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Abstract of the thesis 
The increasing number of analytical methods for the enantioseparation of chiral drug 
molecules is no doubt related to the development of more efficient tools such as chiral 
stationary phases (CSPs) for direct enantioresolution in liquid chromatography (LC). 
In this work, the recognition ability of three new chlorine containing cellulose-based 
chiral stationary phases, Sepapak-2, and Sepapak-4 and Sepapak-5, towards the enantiomers of 
thirteen (13) chiral pharmaceuticals with widely different structures and polarities, has been 
studied in polar organic solvent chromatography (POSC). Since limited information is available 
in literature about these CSPs used with polar organic mobile phases, the influence of 
parameters such as temperature, the percentage of polar (methanol) or non-polar (n-hexane) 
organic modifier, the nature and concentration of the acidic additive, namely trifluoroacetic 
acid (TFA), formic acid (FA) or acetic acid (AcA), in the mobile phase, was first evaluated on 
Sepapak-4 using an univariate approach. In all experiments, acetonitrile was selected as the 
main component of the mobile phase. 
The experimental design methodology was then applied for the screening of these 
factors (except the polar organic modifier), the nature of the basic additive in the mobile phase 
being included as an additional factor. The application of an optimization design (a face 
centered central composite design) led to the evaluation of the effects of different factors on 
enantioresolution for ten of the studied compounds. Furthermore, optimal conditions for the 
enantioseparation of these chiral molecules could be deduced and two conditions for rapid 
screening of chiral compounds on Sepapak-4, namely ACN/0.1% DEA/0.1% TFA/5% n-
hexane and ACN/0.1% DEA/0.2% FA/5% n-hexane, were retained and tested on other drug 
molecules at 25°C.  
A rapid screening strategy for method development including mobile phases containing 
TFA (0.1%), FA (0.2%) or AcA (0.2) was proposed and the behavior of the three chlorinated 
CSPs was compared under these conditions. The following mobile phases were tested at 25°C: 
ACN/0.1% DEA/0.1%TFA, ACN/0.1% DEA/0.2% FA and ACN/0.1% DEA/0.2% AcA. 
Sepapak-2 was found to have an intermediate behaviour leading to lower enantioresolution 
values compared to Sepapak-4 and Sepapak-5. On the other hand, with at maximum four 
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experiments, it was possible to separate the enantiomers of each of the thirteen studied 
compounds.  
In the part of the thesis devoted to the development of applications, tests were 
conducted in order to optimize the enantioresolution of ropivacaine, a local anesthetic, the 
pharmaceutical formulation of which consists of an enantiopure aqueous solution of the S-
enantiomer. A reversal of the elution order of the enantiomers, related to the nature of the 
acidic additive, was observed on both Sepapak-2 and -4. On the contrary, no reversal of the 
enantiomer elution order was found when Sepapak-5 and Chiralcel OD-H, a CSP with cellulose 
tris (3,5-dimethylphenylcarbamate) as chiral selector, were used under the same conditions. 
The best chromatographic conditions for the enantiomeric purity determination of S-
ropivacaine were then selected and the developed method was fully validated according to the 
strategy based on the use of accuracy profiles, which takes into account the total error, i.e. the 
estimation of the systematic and random errors of measurement results. 
 The second application that we have developed deals with the enantiomeric purity 
determination of S-amlodipine in a pharmaceutical formulation. A reversal of the enantiomer 
elution order caused by changes in the concentration of formic acid (FA) in the mobile phase 
was pointed out, using Sepapak-4 and Sepapak-2 as CSPs. Studies on the enantioseparation of 
amlodipine in these chromatographic systems led to the selection of the most suitable CSP and 
the optimal concentration of formic acid in the mobile phase with respect to the elution order 
(R-amlodipine eluting first) and the resolution value. The method was then prevalidated using 
the same approach as for S-ropivacaine. 
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Résumé de la thèse 
Le nombre croissant de méthodes analytiques pour l‟énantioséparation de molécules 
médicamenteuses chirales est sans aucun doute lié au développement d‟outils de plus en plus 
performants tels que de nouvelles phases stationnaires chirales (PSC) pour l‟enantiorésolution 
directe en chromatographie liquide (CL). 
Dans ce travail, le pouvoir de résolution de trois nouvelles PSC constituées de dérivés 
chlorés de phénylcarbamate de cellulose, Sepapak-2, Sepapak-4 et Sepapak-5, vis-à-vis des 
énantiomères de treize (13) molécules thérapeutiques chirales avec des structures et des 
polarités très différentes, a été étudié par chromatographie en phase organique polaire (POSC). 
Ces PSC ayant été peu utilisées jusqu‟à présent avec des phases organiques polaires, l'influence 
des paramètres comme la température, le pourcentage en modificateur organique polaire 
(méthanol) ou apolaire (n-hexane), la nature et la concentration de l‟additif acide, à savoir 
l'acide trifluoroacétique (TFA), l'acide formique (FA) ou l'acide acétique (AcA), dans la phase 
mobile, a d'abord été évaluée sur Sepapak-4 au moyen d‟une approche univariée. Dans tous les 
cas, l'acétonitrile a été choisi comme principal composant de la phase mobile.  
La méthodologie des plans d‟expériences a ensuite été appliquée pour le criblage de ces 
facteurs (sauf le modificateur organique polaire), la nature de l'additif basique dans la phase 
mobile étant par ailleurs incluse comme facteur supplémentaire. L'application d'un plan 
d'optimisation (plan central composite à face centrée) a permis l‟évaluation des effets des 
différents facteurs sur l‟énantiorésolution de dix des composés chiraux étudiés. En outre, les 
conditions optimales pour l‟énantiorésolution de ces molécules chirales ont pu être déduites et 
deux conditions pour le criblage rapide de composés chiraux sur Sepapak-4, à savoir 
ACN/0,1% DEA/0,1% TFA/5% n-hexane et ACN/0,1% DEA/0,2 % FA/ 5% n-hexane, ont été 
retenues et testées sur d'autres molécules chirales à 25 °C.  
Une stratégie de criblage rapide pour le développement de méthodes, incluant des 
phases mobiles contenant du TFA (0,1%), du FA (0,2%) ou de l‟AcA (0,2%) a été proposée et 
le pouvoir de résolution de ces trois PSC chlorées a été comparé dans ces conditions. Les 
phases mobiles suivantes ont été testées à 25°C: ACN/0,1% DEA/0,1% TFA, ACN/0,1% 
DEA/0,2 % FA et ACN/0,1% DEA/0,2% AcA. Un comportement intermédiaire a été observé 
dans le cas de Sepapak-2, entraînant des valeurs d‟énantiorésolution plus faibles par rapport à 
celles obtenues avec Sepapak-4 et Sepapak-5. Par ailleurs, il a été possible de séparer, à l‟aide 
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de quatre expériences au maximum, les énantiomères de chacun des treize composés chiraux 
étudiés.  
Dans la partie de la thèse consacrée au développement d‟applications, une série de tests 
ont été réalisés afin d'optimiser l'énantiorésolution de la ropivacaïne, un anesthésique local, 
dont la formulation pharmaceutique se compose d'une solution aqueuse de S-ropivacaïne. Une 
inversion de l'ordre d'élution des énantiomères de la ropivacaïne en fonction de la nature de 
l'additif acide dans la phase mobile a été observée sur les deux PSC, Sepapak-2 et Sepapak-4. 
Par contre, aucune inversion de l'ordre d'élution des énantiomères de la ropivacaïne n‟a été 
observée lorsque Sepapak-5 et Chiralcel OD-H, dont la cellulose tris (3,5-
diméthylphénylcarbamate) constitue le sélecteur chiral, ont été utilisées dans les mêmes 
conditions. Les meilleures conditions chromatographiques pour la détermination de la pureté 
énantiomérique de la S-ropivacaïne ont ensuite été sélectionnées et la méthode développée a été 
entièrement validée au moyen de la stratégie basée sur l'utilisation du profil d‟exactitude, qui 
tient compte de l'erreur totale, c'est-à-dire de l'estimation des erreurs systématiques et aléatoires 
des résultats de mesure. 
La seconde application que nous avons mise au point concerne la détermination de la 
pureté énantiomérique de la S-amlodipine dans une formulation pharmaceutique. Une inversion 
de l'ordre d'élution des énantiomères provoquée par le changement de la concentration d'acide 
formique (FA) dans la phase mobile a été mise en évidence, sur Sepapak-2 et Sepapak-4. 
L‟étude de l‟énantiorésolution de l'amlodipine dans ces systèmes chromatographiques a permis 
la sélection de la PSC la plus adéquate et de la concentration optimale d'acide formique dans la 
phase mobile en ce qui concerne l'ordre d'élution (la R-amlodipine éluant en premier) et la 
valeur de résolution. La méthode a ensuite été prévalidée en utilisant la même approche que 
pour la S-ropivacaïne. 
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I.1. Background 
 
It is well known that many implications of chirality are due to the fact that the 
enantiomers of chiral drugs can have different pharmacological activities in relation with their 
spatial configuration. Indeed, many enantiomerically pure natural compounds such as sugars, 
amino acids and proteins are involved in the majority of biological processes. Thus, the nature 
is capable of producing, processing and recognizing chiral compounds with an outstanding 
specificity. For example, most chemists are familiar with the role of chirality in odorants
 
such 
as (4S)-(+)-carvone, which has a distinct caraway odor, as compared to (4R)-(-)-carvone, 
which has a characteristically sweet spearmint odor. We can also distinguish enantiomers of 
limonene with our sense of smell: R-enantiomer smells orange while the S-enantiomer smells 
lemon [1]. Although the role of chirality in odor perception is still a rather modern area of 
interest, it should be noted that more than 285 enantiomeric pairs (570 enantiomers) are 
known to exhibit either differing odors or odor intensities [2]. 
Over the last five decades, there has been a particularly great interest in the biological 
activity, both pharmacological and toxicological, of the enantiomers of chiral drugs since the 
disaster of the tranquillizer drug called thalidomide. Indeed, thalidomide was manufactured 
and sold as a racemate of N-phtalylglutamic acid imide, the S-isomer of which was 
teratogenic and caused serious fetal malformations called phocomelia. For this reason, the 
control and determination of the enantiomeric composition of chiral drug substances have 
become key issues for both the pharmaceutical industry and regulatory agencies [3]. 
Nowadays, most of the top selling drugs around the world are administered as single 
enantiomers, possessing the desired physiological activity [4]. Thus the development of 
methods for the production of enantiomerically pure compounds and the assessment of their 
enantiomeric purity have become more and more important specially in life science 
applications, such as biochemical, toxicological, forensic and pharmaceutical research. As a 
result of these news trends, there has been a tremendous impetus to develop separation 
methods based on chiral LC, both on analytical and preparative scales since an asymmetrical 
synthesis of enantiomers is very expensive. As the result, a great number of chiral stationary 
phases (CSPs) were commercialized and among them, polysaccharide based CSPs have been 
most extensively studied since there are suitable for both analytical and preparative scale 
enantioseparations.  
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I.2. Stereochemistry and pharmacology 
 
Earlier in the 18
th
 century, Carl Wilhelm Scheele discovered tartaric acid from tartar 
(the potassium salt of tartaric acid, deposited on barrels and corks during fermentation of 
grape juice) while the view of light as a beam of asymmetric particles was discovered. To 
explain this newly observed light phenomenon associated with reflection, Malus in 1806 
claimed that these particles were bipolar. Reflection causes these dipoles to become oriented 
to produce polarized light and this light has a plane of polarization. In 1815, Biot, a classmate 
of Malus, noted that certain natural organic compounds (liquids or solutions) rotate plane 
polarized light, suggesting that this optical activity was a molecular property. In 1838, he 
discovered tartaric acid from grape juice fermentation to rotate plane polarized light in a 
clockwise direction while he made the reverse observation for racemic acid. 
Ten years later, Pasteur repeated his earlier work on racemic acid, and this time he 
observed that crystallization of the sodium ammonium salt of this acid produced mirror image 
crystals that he separated by hand. These two crystalline forms were dissymmetric, non- 
superimposable mirror images and their equimolar solutions showed equal but opposite 
optical activity. From these observations, Pasteur concluded that optical activity is based on 
dissymmetry, not only at the crystalline level but also at the molecular level [5]. Thus, 
Pasteur‟s work paved the way for subsequent work of Van‟t Hoff and Le Bel, who postulated 
in 1874 the tetrahedral nature of carbon (carbon with 4 attachments is tetrahedral and a 
molecule having a tetrahedral carbon with 4 different attachments may exist as a pair of 
isomers) and the basic rules for modern stereochemistry. 
Towards the end of the 19
th
 century the role of chirality in biological activity began to 
receive serious attention. Two lines of investigation were pursued: one focused on the 
metabolic fate of chiral compounds while the other examined their pharmacological activity. 
The first report on enantioselectivity in what may be considered a pharmacological effect was 
in 1886, when (+)-asparagine was found to have a sweet taste while (-)-asparagine was 
tasteless [6]. Pasteur, aware of the finding, interpreted the results as an indication of the 
presence of a monochiral compound in the nervous system of taste, suggesting that the 
interactions of the asparagine enantiomers with the chiral biological mediator were different 
[8-10]. 
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I.2.1. Stereochemistry: definition, terminology and nomenclature 
 
Stereochemistry is the study of the static and dynamic aspects of the three-
dimensional shapes of molecules [11]. It involves studies of chemistry properties of molecules 
that possess identical constitution, but differ in the arrangement of their atoms in space, 
namely stereoisomers. They can have one or more carbon atoms and sometimes another atom 
bearing 4 different atoms or group of atoms.  
One molecule containing one stereocenter (a carbon atom or another atom bearing 4 
different atoms or groups of atoms) is a chiral molecule and has two stereoisomers which are 
nonsuperimposable with their mirror image, called enantiomers. 
Chirality is often illustrated with the idea of left- and right-handedness:
 
a left hand 
and right hand are mirror images of each other and are not superimposable. The two mirror 
images of a chiral molecule shown in Figure 1 are enantiomers. 
However, a necessary and sufficient criterion for chirality in a rigid molecule is the 
absence of any improper symmetry elements. Otherwise, atoms other than carbon can exhibit 
chirality such as sulphur, nitrogen and phosphorus which are the most common atoms in 
stereocenters after carbon. 
 
 
 
 
 
 
 
Figure 1. Non-superimposable mirror images are enantiomers. 
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 When a molecule has more than one stereocenter, it can have 2
n
 stereoisomers (n is the 
number of stereocenters) called disastereoisomers which are not nonsuperimposable mirror 
images but have different chemical and physical properties in any type of environment. 
Unlike diastereoisomers, enantiomers display the same chemical and physical properties in an 
achiral environment. They have the ability to rotate plane polarized light and thus are called 
optically active compounds or sometimes optical antipodes. An enantiomer that provides a 
clockwise rotation is called dextrorotatory [(d) or (+)] while that providing an anticlockwise 
rotation is called levorotatory [(l) or (-)]. A mixture of equal quantities of the two enantiomers 
results in a non-optically active mixture or racemate [(±) or (d,l)]. The degree of rotation of 
plane-polarized light (α) is related to the molecule studied, but also to its concentration, the 
length of the polarimeter tube, wavelength, temperature and solvent. When it is called specific 
rotation, [α]λ
t
 is the rotation observed for a solution containing 1 g.ml
-1
 in 1 dm cell at λ nm 
and t °C [12, 13].  
In biochemistry, the common nomenclature system used is the D (Dextrogyrate) / L 
(Laevogyrate) based system since this system is used primarily for sugars and amino acids. To 
name complex carbohydrates or amino acids, one draws a similar Fischer projection where 
the CH2OH or R is at the bottom and the carbonyl group (aldehyde, ketone, or carboxylic 
acid) is at the top. The D descriptor is used when the OH or NH2 on the penultimate (second 
from the bottom) carbon points to the right and L is used when the OH or NH2 on the same 
carbon points to the left. It is commonly stated that most natural amino acids are L, while 
natural sugars are D.  
For chemists, the R (rectus) / S (sinister) system is the most important nomenclature 
system for notification of absolute configuration of enantiomers. The Cahn-Ingold-Prelog 
(CIP) rule assigns R or S configuration to the enantiomer. 
According to the CIP sequencing rules, the four substituents of a tetrahedral chirality 
center (stereocenter) are ranked in order of decreasing atomic number of the atoms directly 
bonded to the chirality center. Isotopes of the same chemical element are listed in order of 
decreasing atomic mass. When two or more atoms bonded to the chirality center have the 
same atomic number, the second atoms are used to rank the substituents. If the second atoms 
are also the same, the third are used, and so on. Multiple bonds are counted as the 
corresponding number of single bonds. The substituent with lowest precedence is visualized 
as pointing away from the viewer, so that the remaining three substituents are then placed in 
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order of decreasing precedence, a > b > c > d. If the order is clockwise, then the symbol R is 
assigned to the enantiomer while symbol S is assigned when the order is anticlockwise [14-
18]. The application of these CIP rules to enantiomers of glyceraldehyde (cf. Fig. 2) led to the 
following order: OH> CHO> CH2OH> H. 
Thus, the absolute configuration of glyceraldehyde enantiomers can be assigned as shown in 
Figure 2. 
 
 
 
 
Figure 2. Absolute configuration of enantiomers of glyceraldehydes. 
It should be emphasized that the three previous systems of nomenclature [(d, l) or (+, -), (D, 
L) and (R, S)] are mutually exclusive. R enantiomer of one compound may be either 
dextrorotatory or levorotatory, while another compound may have its S enantiomer as 
dextrorotatory. When a molecule contains more than one asymmetric carbon, the absolute 
configuration of each numbered stereocenter should be identified at the beginning of the name 
[19].  
 
I.2.2. Pharmacological implication of chirality 
 
The presence of one stereocenter in the absolute structure of a therapeutic molecule 
can lead to different situations according to toxicological and pharmacological properties. As 
the two stereoisomers of the drug have different configurations, their complementary binding 
sites (receptors, enzymes, etc) are also expected to be different. Thus the stereoisomer 
(commonly referred to as “eutomer”) binding precisely to the target sites could induce the 
therapeutic activity while the other stereoisomer (distomer) may bind weakly, not at all the 
relevant site or may bind precisely to other sites that are not the intended targets. In this way, 
whenever a drug is commercialized as a racemate, the eutomer may be active while the other 
stereoisomer may have: 
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- no activity, 
- quantitatively and qualitatively the same activity,  
- qualitatively the same type of activity but lower intensity, 
- a completely separate beneficial activity, 
- a completely separate adverse activity. 
In the first three cases, the racemic drug is considered to be safe and thus there is no 
need to perform resolution of enantiomers. Otherwise, the synergistic activity (completely 
separate beneficial activity) of eutomer and distomer in racemate is also interesting for 
therapeutic purpose. The enantiomers of cicletanine clearly illustrate this case. Cicletanine is a 
furopyrine low-ceiling diuretic drug, usually used in the treatment of hypertension. The S-(-) 
stereoisomer decreases peripheral vascular resistance and in so doing improves the 
antihypertensive effect of R-(+) cicletanine taken alone [20]. The most uncomfortable 
situation for drug discovery remains the last case. When the distomer has toxic activity, like 
S-(-)-enantiomer of thalidomide or D-dopa, the need for production of the single eutomer by 
means of enantioselective method of synthesis or purification becomes a matter of legal 
requirements.  
However, the phenomenon of “chiral inversion” (conversion of one enantiomer into its 
mirror image) adds to the complexity. Although S-thalidomide is teratogenic, both R and S 
enantiomers of thalidomide inverted rapidly to the racemic mixture in the liver [21]. Hence 
the claims that R-thalidomide could be safer and that the tragedy could have been prevented 
by using single R-thalidomide are not valid. 
Since it is well known that amino acids, carbohydrates and macromolecules like 
plasma proteins, nuclear and membrane receptors are asymmetric, their interactions with 
chiral compounds may be enantioselective and lead to different pharmacokinetic parameters 
for each enantiomer. In the same way, the enzyme system activity could be different from an 
enantiomer to an other entailing different metabolites in the process. Thus all the 
pharmacokinetic processes, namely absorption, distribution, metabolism and excretion, may 
be influenced by chirality. Indeed, active transport processes may discriminate between 
enantiomers, with implications on biovailability, e.g., esomeprazole is more bioavailable than 
racemic omeprazole [22]. The volume of distribution of levocetirizine has been shown to be 
significantly smaller than that of its dextro enantiomer, which is a positive aspect in terms of 
both safety and efficacy. Glucuronide conjugates and the lateral chain oxidized product of 
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(S)-(-)-propranolol metabolism are more important than that of its optical antipode, (R)-(+) 
[23]. Otherwise, enantiomers of drugs are often metabolized at different rates and this could 
result in accumulation of the inactive enantiomer or rapid elimination of the active one and 
vice versa. Thus the determination of pharmacological and toxicological activities of each 
stereoisomer of a chiral compound constitutes an important step in drug development. 
 
 
I.3. Chirality and interest for pharmaceutical industry 
 
Since single stereoisomers may exhibit quite different bio-activities, pharmacological 
and toxicological behaviors within the chiral environment of biological systems, drug 
stereochemistry became an important issue for pharmaceutical industry and the regulatory 
authorities [24-27]. The development of single enantiomers versus racemates or the 
introduction of a single enantiomer following the development of the racemic mixture, 
namely “chiral switch”, appears to be the new trends either for economic purposes or public 
health consideration. The single enantiomer can often offer advantages in potency, efficacy 
and/or safety to patients over the corresponding racemate. The economic interests are obvious 
and essential driving forces in development of advantageous technology for chiral drugs [28]. 
Otherwise, if in fact a single enantiomer can demonstrate an actual pharmaceutical advantage, 
it could have a quicker discovery turnaround time, a more streamlined development, a 
smoother approval process, and a quicker appearance in the market. This latter consideration 
is economically interesting since the development of a new drug costs more than 600 million 
euros and the time between its development and its market approval is over a decade [29]. 
Moreover, the commercialization of a single enantiomer of a previously approved racemate, 
may be patentable and therefore, provides additional market exclusivity via trading license. 
Levosalbutamol, S-ketamine, S-omeprazole (esomeprazole), levobupivacaine and S-
amlodipine are some chiral switches that have yielded safer alternatives and provide 
additional patents for pharmaceutical industries. 
It should be emphasized that discovery, development and worldwide sale of 
enantiomerically pure chiral drugs have been increasingly important over the last two 
decades. The worldwide sale of chiral drugs in single-enantiomer forms increased annually 
from 27% (56 billion euros) in 1996, 29% (1998), 32% (1999), 34% (2000), 38% (2001) to an 
estimated 39% (114 billion euros) in 2002 [30]. 
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Obviously, chirality is of considerable importance in the pharmaceutical industry 
either for both economic and therapeutic standpoints or for regulatory purposes. Thus, 
increasing demand for enantiomerically pure chiral compounds has stimulated a rapid 
development of enantioselective synthesis methodologies and business of enantiopure 
compounds [31]. Simultaneously, this new trend produces an increase in the demand for 
stereoselective separation techniques and analytical methods for accurate determination of 
enantiopure compounds. Over the past two decades, tremendous progress was made in these 
enantioresolution methods. The development of chiral stationary phases (CSPs) for liquid 
chromatography (LC), supercritical fluid chromatography (SFC) and gas chromatography 
(GC) and chiral selectors for capillary electrophoresis, has opened a new dimension in the 
enantioseparation technologies. An impressive number of CSPs is now available for either 
analytical or preparative purposes. 
 
 
I.4. Chiral separations 
 
Many analytical techniques enable the enantioresolution of chiral compounds, namely 
liquid chromatography (LC), supercritical fluid chromatography (SFC), gas chromatography 
(GC), capillary electrophoresis (CE), thin layer chromatography (TLC), micellar 
electrokinetic chromatography (MEKC) and recently capillary electrochromatography (CEC) 
[32]. Even though some techniques are quite complementary, it should be emphasized that 
liquid chromatography has grown significantly as a simple and practical method applicable 
for both analytical and preparative purposes [33-35]. In most techniques, there are two 
strategies for enantiomeric separation: the direct and the indirect methods [34]. 
The most important factor in indirect enantioseparation method is the availability of 
optically pure chiral derivatizing reagents converting racemic mixtures into mixture of 
diastereoisomeric derivatives differing in physicochemical properties and therefore separated 
in an achiral environment by chromatographic or electrophoresis techniques. The separation 
can also be performed by crystallization or distillation [36]. A broad spectrum of monochiral 
derivatization reagents has been developed for GC, LC and CE [30]. (+)-1-(9-fluorenyl)-
ethylchloroformate [(+)-FLEC], (S)-(-)-N-(fluoroacetyl)-prolyl chloride, 1-phenyl-
ethylcyanate, (S)-(+)-2-methoxy-2-(1-naphthyl)propionic acid and N-methyl-N-
bis(trifluoroacetamide) (MBTFA) are some of the usual monochiral derivatizing reagents [37-
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40]. This indirect method appears particularly interesting for the enantiomeric separation of 
sugars, amino acids, peptides, etc. The sensitivity and the selectivity of the method could be 
improved through the addition of the chiral derivatization reagent. Fluorescent reagents are 
specially interesting to enhance detection sensitivity for LC and CE [41,42]. A disadvantage 
to this approach is the additional step of reaction between the enantiomers and the 
derivatizing reagent. Moreover, the chiral derivatizing reagent must be controlled so that no 
racemization has taken place during the reaction.  
The direct method involves the separation of enantiomers in a chiral environment and 
seems to be easiest and most simple. There are two principles that enable one to obtain 
enantioresolution by this method.  
The first principle creates a chiral environment with chiral selector (cyclodextrin, α-
amino acid associated with metallic ion, etc.) added to the mobile phase or the background 
electrolyte in analytical methods such as LC, TLC and CE. In chromatographic techniques 
achiral stationary phases are used to perform the separation. In many cases, this approach 
gives good results but the enantioresolution is influenced by pH, temperature, the 
concentration of organic modifier in the mobile phase, the type and purity of the chiral 
selector and the nature of the stationary phase for LC and TLC. Otherwise, the high cost of 
chiral selectors and the compatibility between the detection mode and the chiral reagent make 
this approach less praticable and expensive in LC. Thus it is mostly used in capillary 
electrophoresis where the consumption of chiral selector is lower [32, 43-46]. Nowadays, this 
technique has gained a broad scope of application in the field of enantioseparations with the 
use of cyclodextrins and derivatives as chiral selectors [13, 47]. 
The second principle is based on a use of a chiral stationary phase (CSP) where the 
chiral selector is adsorbed or chemically bonded to a solid phase. These CSPs are mainly used 
in LC and SFC [48-50]. The method is based on the discriminatory ability of the CSP towards 
the two enantiomers. According to this recognition ability, the CSP can retain by specific 
interactions an enantiomer while the second is being eluted or less strongly retained. Even 
though many models for the requirements to obtain chiral recognition have been described in 
the literature, the first and most reliable is the three-point model that was proposed by 
Dalgliesh [51]. This model postulates that three interactions must take place and at least one 
has to be stereoselective to enable chiral resolution. In other words, if the CSP interacts with 
three different functional groups (AA‟, BB‟, CC‟) near the stereocenter of the analyte, the 
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chiral discrimination of its enantiomers can be performed (cf. Fig. 3). On the contrary the 
chiral recognition cannot be performed in the case where only two functional groups near the 
stereocenter of the analyte interact with the CSP. The interactions often involve hydrogen 
bonds and dipole stacking (aromatic interactions) but are sometimes associated with ionic 
attractions [31, 32, 40, 52].  
Others techniques such as capillary electrochromatography (CEC) and capillary liquid 
chromatography (CLC), also use CSPs packed in a capillary, to perform enantioseparation of 
chiral compounds [52]. 
 
 
 
 
 
 
 
 
 
Figure 3. Three points interaction model. 
 
Unlike CLC, capillary electrochromatography (CEC) is a hybrid technique between 
CE and LC. The driving force allowing the separation in this technique to proceed is the 
electro-osmotic flow (EOF) obtained by applying a voltage onto the capillary [54-55]. These 
techniques allow both direct approaches for enantioseparation. However, the comparison of 
the two techniques revealed significant advantages for CEC [53].  
Even though the majority of enantioseparations can be performed on chiral stationary 
phases in LC, it should be emphasized that there is no universal CSP [34]. Thus, a tremedous 
number of CSPs have been developed and several hundreds are commercially available. 
Therefore, the enantioseparation of a target chiral drug depends on the choice of a suitable 
combination between a CSP and a LC mobile phase.  
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I.5. Direct LC Enantioseparation: Chiral Stationary Phases (CSPs) and Mobile 
Phases 
I.5.1. CSPs: Classification 
 
The key for the success of enantiomer separations is often based on a proper selection 
of a suitable chiral stationary phase having a chiral distinction capability for the target solute 
enantiomers. For this purpose, the knowledge of existing chiral stationary phases and their 
properties are of major importance in direct LC enantioseparation. Although many CSPs are 
commercially available, they can be classified according to two main criteria: chiral 
recognition mechanism and chiral selector nature. However, the classification changes from 
one author to another because of the rapid development of CSPs and a better understanding of 
mechanisms underlying. 
 Earlier in 1987, Wainer‟s classification of CSPs which was based on the mechanism 
of chiral recognition depicted in five groups [57]:  
Type I. where the solute-CSP complexes are formed by attractive interactions, 
 hydrogen bonding, π-π interactions, dipole stacking, between the solute and CSP; 
Type II. where the primary mechanism for formation of the solute-CSP complex is 
 through attractive interactions but where inclusion complexes also play an important 
 role; 
Type III. where the solute enters into chiral cavities within the CSP to form inclusion 
 complexes; 
Type IV. where the solute is part of a diastereomeric metal complex (chiral ligand 
 exchange chromatography); 
Type V. where the CSP is a protein and the solute-CSP complexes are based upon c
 ombinations of hydrophobic and polar interactions.  
Three years later, taking into account the new available CSPs, Gübitz classified the 
CSPs in five groups based on the major interactions between chiral solute and CSP [59]: 
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(i) Chiral phases with cavities (cellulose derivatives, cyclodextrins, synthetic chiral 
polymers, chiral crown ethers and chiral imprinted polymers); 
(ii) Chiral affinity phases (bovine serum albumin (BSA), human serum albumin 
(HSA), α1-glycoprotein (AGP), ovomucoid and avidin); 
(iii)  Chiral phases based on multiple hydrogen bonding formation (amino acid amide 
and tartaric acid amide phases); 
(iv)  Chiral π-donor and π-acceptor phases (Pirkle phases or brush type phases); 
(v)  Chiral ligand exchange chromatography phases (polystyrene-divinylbenzene 
polymers containing amino acid residues complexed with metal ions). 
Even though this classification seems clear, Siret et al. proposed a restrictive 
classification with four groups related to both recognition mechanism and chiral selector 
structure [60]. In their classification, ligand exchange and chiral π-donor and π-acceptor 
phases were mixed in a group in which the chiral recognition involves superficial complexes 
formation (Type I). The chiral phases with cavities group without cellulose derivatives, was 
called Type II. This group comprises two sub-groups: Type IIA, involving formation of 
inclusion complexes due to the hydrophobic moiety of the solute molecule which must be 
relatively “tigh fitted” to the hydrophobic cavity of the selector (e.g. cyclodextrin) and Type 
IIB, involving hydrophilic interactions. A special group was dedicated to protein derived 
CSPs (Type IV) and the type III was made of natural (Type IIIA) or synthetic polymer-based 
CSPs (Type IIIB).  
Recently, Okamoto et al. [51] classified CSPs for LC into two groups while 
Lämmerhofer [61] proposed three groups. Both authors take into account only the size of the 
chiral selectors to sort out the presently available CSPs.  
In the classification of Okamoto et al., the first type of CSP consists of optically 
active small molecules, which are usually immobilized on silica gel or on organic polymer 
gel as achiral supports (brush-type CSPs). The authors put into this group ligand-exchange 
type, crown-ether-based, cyclodextrin-based, donor-acceptor-type, (aglycone)-glycopeptide-
based and ion-exchange-type CSPs. The second type of CSP consists of optically active 
polymers, which are further divided into synthetic and natural polymers. Molecular 
imprinted-type, poly(meth)acrylamide-based, polymethacrylate-based, polyamide-based and 
tartardiamide-based CSPs were described as synthetic polymer-based CSPs while protein-
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based and polysaccharide-based CSPs (including those coated or immobilized on silica gel) 
are natural polymer-based CSPs.  
Lämmerhofer distinguishes CSPs with macromolecular selectors (biopolymers like 
proteins and polysaccharide derivatives, and synthetic polymers such as polytartaramides, 
poly (meth) acrylamides), those with macrocyclic selectors (cyclodextrins, macrocyclic 
antibiotics and chiral crown ethers) and CSPs with low molecular mass selectors (donor-
acceptor (Pirkle-type), chiral ion exchange type and ligand (chelating agents) selectors). 
These different types of CSPs are presented in Table 1 with the corresponding chiral selectors, 
the recognition mechanisms and some examples of commercialized CSPs. 
It should be emphasized that more than 90% of chiral separations by LC are performed 
using polysaccharide-based CSPs. Futhermore, the newly developed cellulose or amylose 
based CSPs by immobilizing either cellulose tris (3,5-dimethylphenylcarbamate) or amylose 
tris (3,5-dimethylphenylcarbamate) onto silica gel, expand the versatility and application 
range via their extended choice of mobile phases, resulting in an enormous flexibility for 
method development [62,63]. The recently mixed methyl/chloro or dichloro-substituted 
polysaccharide derivatives CSPs introduced as Sepapak-2, -3, -4 or -5 by Sepaserve, provide 
some complementary enantiorecognition profiles and enable multimodal chromatographic 
use. These chlorine containing polysaccharide-based CSPs will be of main interest in the 
present thesis. 
 
 
I.5.2. Interest of non aqueous polar mobile phases in chiral separations 
 
Although chiral stationary phases are dedicated to normal phase and reversed phase 
systems which cover almost completely the potential applications of CSPs in LC, the use of a 
polar organic solvent as the main component of the mobile phase has become increasingly 
popular [57, 65-67]. This system, first called “polar organic mode” or “polar organic solvent 
chromatography” (POSC) by Amstrong et al. consists of the use of only organic solvents 
(excluding water), usually methanol, ethanol, acetonitrile or their combinations in the mobile 
phase [68]. Even if this chromatographic mode started with antibiotic and macrocyclic-based 
CSPs, it is nowadays extended to the other CSPs because of its advantages. The polar organic 
mode or POSC may offer the advantages of the reversed-phase mode through: 
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- an increase of solubility of some analytes which are often less soluble in aqueous 
solvents,  
- stronger ionic and polar interactions, allowing alternative chiral recognition 
mechanisms. 
This chromatographic mode may also offer some advantages of normal-phase LC and 
SFC since the working pressure is lower due to the low viscosity of organic solvents which 
are easy evaporated, especially in preparative scale applications, and separation efficiency is 
often higher [66,69]. Futhermore, the use of acidic or basic additives has become of great 
interest. Indeed, Ye et al. demonstrated the effect of acidic and basic (amine) additives on 
enantioselectivity for phenylalanine analogs using Chiralpak AD as CSP in normal-phase 
mode [70,71] and then later in POSC. Thus the combination of this polar organic mode with 
acidic and basic additives may offer alternative possibilities for method development and 
optimization either by univariate or multivariate techniques (experimental designs). 
 
 
I.6. Method development: experimental designs 
 
The development of an analytical method usually needs the study of numerous factors. 
In order to determine initially the factors which could have an impact on the selected 
response(s), a screening test is often performed. It allows reducing potentially the number of 
factors that need to be investigated in further experimentations. The objective is to eliminate 
non significant factors before investing time and money in a more elaborate testing. The 
relevant factors can be optimized through a set of experiments that will enable one to get the 
optimal conditions which are the best combination of factors levels that fit the purpose of the 
study. To achieve these two steps of method development, two approaches can be chosen: the 
univariate approach and the multivariate approach. 
The univariate or classical approach consists of selecting several factors which are 
varied one-by-one to assess their influence on the response(s) of interest. This sequential 
approach allows a quite good view of the impact of each factor on the targeted response but 
there is no possibility to visualize interaction effects which can play major role in the 
phenomena governing this response. Furthermore the univariate approach sounds less cost-
effective and is time-consuming. There may be also a potential loss in evaluating power when 
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not analyzing the data simultaneously. Nevertheless, this method is adequate for method 
development when no information is available on factors likely to influence the targeted 
response(s).  
The multivariate approach or experimental design is a core area of study in 
chemometrics. It is an even better alternative because for a given number of experiments the 
experimental domain is more completely covered and interaction effects between factors can 
be evaluated. An experimental design can be considered as a series of experiments that, in 
general, are defined a priori and allow the influence of a predefined number of factors in a 
predefined number of experiments to be evaluated [72]. 
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Table 1: Classification of CSPs and the mechanism of their recognition [12,52,57-61]. 
Groups Sub-groups Chiral selector structure Mecanism of chiral recognition Advantages and drawbacks (e.g.) 
CSPs with 
low 
molecular 
mass 
selectors 
Π-donor-acceptor- type 
(Pirkle type) 
(R)-3,5-dinitrobenzoyl-
phénylglycine 
1,2-trans-diaminocyclo 
hexane  
1,2-trans- 
diphenylethylenediamine 
The π-π stacking interaction 
between the electron-deficient 3,5-
dinitrobenzoyl-groups and electron-
rich aromatic groups plays a 
significantly important role in 
discriminating enantiomers of 
chiral compounds in addition to 
hydrogen bonding, dipole-dipole 
and steric interactions. 
Compatibility with all conventional 
mobile phases in LC and SFC; good 
stability; efficiency equivalent to a 
classical grafted silica; possibility of 
use on a preparative scale; less 
expensive but the scope of application 
is still limited to compounds of low or 
medium polarity. (Whelko-01, 
ULMO and DACH-DNB from Regis; 
Chirex 3005, 3020 and 3022 from 
Phenomenex). 
Ligand-exchange-type amino acid like L-proline, 
valine or  
alanine immobilized onto 
an organic matrix (poly 
(styrene divinyl-benzene)) 
or onto silica 
Reversible coordination of 
chelating analyte species from the 
mobile phase into coordination 
sphere of a metal ion that is 
immobilized by complexation with 
a chelating chiral selector forming 
mixed ternary metal ion/selector/ 
Good stability, high selectivity 
values, less expensive but poor 
efficiency and the scope of 
application is limited to bidentate or 
tridentate ligands (Chiralpak MA+ 
from Daicel, Nucleosil Chiral-1 from 
Macherey-Nagel and Chirex 3126 
 Chapter I. Introduction 
 
19 
solute complexes. Depending on 
the steric and functional properties 
of the analytes, these 
diastereomeric ternary chelate 
complexes show different rates of 
formation and/or thermodynamic 
stabilities, giving rise to different 
retention times of corresponding 
solute enantiomers. 
from Phenomenex). 
Crown ether-based 
CSPs 
Chiral crown ethers 
bearing optically active 
binaphthyl and tartric acid 
units and phenolic pseudo 
chiral crown ethers. 
Generated chiral ammonium ions 
can bind enantioselectively to 
macrocyclic crown ether through 
inclusion complexation driven by 
triple hydrogen bond formation 
between the ammonium ion and 
three oxygens of the crown ether. 
This CSPs run with strongly acidic 
aqueous eluents (pH between 1 and 
3.5) which ensure full protonation 
of the solutes amino functionality. 
Good stability, high selectivity but 
application spectrum essentially 
restricted to primary amines (amino 
acids, N-acetyl amino acids, amino 
acid esters and amides, di- and 
tripeptides, amino alcohols and chiral 
drugs with free primary amino groups 
[59] (Crownpak CR from Daicel, 
.Chirosil RCA (+) and Chirosil SCA 
(-) from Regis). 
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 Cyclodextrin-based 
CSPs (Amstrong and 
deMond, 1984) 
Cyclodextrins (CD) with 
six (α-CD), sept (β-CD) or 
eight (γ-CD) glucose units 
connected via α-1,4-
linkages, bonded onto 
silica. 
A two-step mechanism occurs in 
reversed-phase conditions: the 
hydrophobic part of the guest 
molecule penetrates into the CD 
cavity and leads then to the release 
of solvent (water) molecules from 
guest and CD molecules. Further 
stabilization of the complex may 
stem from van der Waals 
interactions inside the cavity while 
additionally supporting hydrophilic 
interactions with hydroxyl groups 
at the upper and lower rim 
(hydrogen bonding, dipole–dipole 
interactions) may take place. In 
polar organic or normal phase 
mode the inner cavity is blocked by 
solvent molecules preventing 
inclusion complexation thus 
enantioselectivity takes place on the 
Good stability, multi-modal in terms 
of elution conditions (normal and 
reversed phase, polar organic mode 
and SFC) but the spectrum of 
application is limited and their low 
loading capacity make them useless 
for preparative separation  
(Cyclobond from ASTEC; ChiraDex 
and ChiraDex Gamma, from Merck; 
Ultron ES-CD, from Shinwa). 
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polar surface of the CD through 
hydrophilic interactions. 
Glycopeptide 
(aglycone)-based CSPs 
(Macrocyclic 
antibiotics CSPs) 
(Amstrong et al, 1994) 
Glycopeptide (aglycone) 
such as: Vancomycin, 
Ristocetin A, Teicoplanin, 
Teicoplanin agycone, 
immobilized onto silica. 
 
The recognition mechanism is not 
well known but all these selectors 
have plenty of potential interaction 
sites closely attached to stereogenic 
centers including various H-
donor/acceptor functionalities, 
aromatic rings for π-π-interaction, 
acidic and basic groups that may be 
involved in electrostatic 
interactions 
These CSPs can be used with a great 
variety of mobile phases and have a 
broad spectrum of application 
(Chirobiotic V, T, R, from ASTEC 
and TAG from Supelco). 
Ion-exchange-type 
CSPs (Lindner and 
Lämmerhofer, 1996) 
 
Cinchona alkaloid deriva-
tives and terguride 
 
With (weakly) acidic mobile 
phases, the quinuclidine nitrogen 
becomes protonated and acts as the 
fixed charge of the chiral anion-
exchanger. Acidic analytes are then 
primarily retained by an ion-
exchange process. 
Excellent recognition abilities for 
chiral acidic compounds (anion-
exchanger-type), high mass loading 
capacities but enantioseparation of 
these compounds preferentially 
restricted to polar organic and 
reversed-phase modes (Chiralpak 
QN-AX and QD-AX from Chiral 
technologies). 
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Synthetic 
polymer-
based 
CSPs 
 
 
 
 
 
 
 
 
 
 
Molecularly imprinted-
type (Wulff and Sarhan, 
1972) 
Cross linked polymer  
gels with enantioselective 
binding cavities prepared 
via a molecular imprinting 
technique. 
The size, shape and stereochemical 
nature of these chiral cavities are 
complementary to the enantiomer 
used as the template. 
Higher enantioselective affinity for 
template enantiomer than with the 
other CSPs. Scope of application with 
biologically active compounds like 
amino acids, peptides, hormones and 
antibiotics. 
Poly(meth)acrylamide-
based CSPs (Baschke, 
1974 and Okamoto, 
1981) 
 
Monomeric optically 
active acrylamide with 
acryloyl- or methacryloyl 
substituted diol silica, 
Monomers adsorbed on 
diol silica silica. 
Monomers adsorbed on 
silica and subsequent 
blocking of silanol groups 
of silica by reaction with 
dimethyloctylchlorosilane. 
The recognition ability on these 
polymers is significantly dependent 
on the synthetic methods. The 
polymers prepared by the radical 
polymerization of optically active 
monomers exhibit a much higher 
chiral recognition than the prepared 
by the reaction of poly(acryloyl 
chloride) with the corresponding 
chiral amines. It has also been 
found that the tacticity of 
polymethacrylamides and helicity 
of the polymers influence their 
chiral recognition abilities [63]. 
High selectivity values for 
atropoisomers and potential 
preparative applications but efficiency 
limited. (Chiralpak OT (+) from 
Daicel, Chiralspher from Merck). 
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 Polymethacrylate-based 
CSPs 
Optically active poly-
methacrylates with one-
handed helical structure 
Polar or hydrophobic interactions 
between the triphenylmethyl groups 
with a chiral propeller structure and 
racemates are important for the 
successful chiral recognition. 
Efficient resolution of racemates 
without any functional group. 
Polyamide-based CSPs 
(Saigo et al, 1985) 
 
Polyamide including 
poly(α-amino acid) immo-
bilized onto cross-linked 
polystyrene. 
Chiral discrimination should 
involve simultaneous interactions 
of aromatic stacking, hydrogen-
bonding with solute but the high-
ordered conformation of the poly 
(α-amino acid) (which takes an α-
helical structure) seems to 
contribute also to the chiral 
recognition. 
 
Tartardiamide-based 
CSPs (Allenmark et al, 
1995) 
Hydrosilylation of C2-
symmetric N,N’-diallyl-L-
tartardiamide derivatives 
with a multifunctional 
hydrosilane on an allyl-
functionalized silica gel 
The retention is mainly caused by 
the hydrogen-bonding ability of the 
analyte 
A large number of neutral as well as 
acidic or basic drug racemates can be 
resolved without derivatization 
(Kromasil CHI-TBB from Eka 
Chemicals AB). 
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Natural 
polymer-
based 
CSPs 
 
 
 
 
 
 
Protein-based CSPs α1-Glycoprotein acid (α1-
AGP) 
Ovomucoid (OVM) 
Human Serum Albumin 
(HSA), 
Bovine Serum Albumin 
(BSA),  
Cellobiohydrolase (CBH) 
or Avidin, immobilized on 
silica 
Their chiral recognition mechanism 
is not yet well known. However, 
the immobilized protein should 
have some regions capable of 
forming enantioselective cavities 
for many targeted compounds with 
acidic, basic amide and hydroxyl 
groups. The enantioselectivity 
could involve hydrophobic, 
hydrophilic, ionic and π-π 
interactions. Nevertheless, the 
mechanism depends on the 
tridimensionnal structure of the 
immobized protein, which is related 
to the pH of the mobile phase and 
the organic modifier (nature and 
quantity). 
Many applications in pharmaceutical 
enantioseparations and bioanalytical 
studies but low stability, efficiency 
and reproductibility and not useful for 
preparative purposes due to a limited 
number of recognition sites leading to 
a lack of sufficient loading capability. 
(Chiral-HSA, Chiral-AGP and Chiral-
CBH from Chiral technologies: Regis, 
Ultron ES-OVM and Ultron ES-
Pepsin from Shinwa Chemicals, 
Resolvosil BSA from Macherey 
Nagel). 
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 Polysaccharide-based 
CSPs 
 
Cellulose and amylose 
esters (triacetate, benzoate, 
cinnamate) or phenyl-
carbamates, adsorbed or 
immobilized onto silica 
gel, 
 
Chiral recognition often depends on 
the higher order structure of the 
chiral polymers and also on the 
substituents introduced on the 
phenyl moities. However, 
enantioseparation may be governed 
by the π-π, σ-π stacking 
interactions, but hydrogen bonding 
and dipole-induced dipole 
interaction are also essential. 
Good stability, use in both LC and 
SFC modes and recognized as the 
most powerful CSPs for both 
analytical and preparative separations, 
but very large  choice (Chiralcel OD, 
ODH, OD-R, OA, OC, OF, OJ or OK, 
Chiralpak AD or AS and Chiralpak 
IA, IB or IC from Daicel; Sepapak-2 
and -4 from Sepaserve equivalent to 
Lux cellulose 2 and 4 from 
Phenomenex; Cellulose Cel-AC-
40XF from Macherey- Nagel). 
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Otherwise, the objective of an experimental design is to plan and conduct experiments 
in order to extract the maximum amount of information from the collected data in the 
presence of noise and the smallest number of experiments. Consequently the main difference 
with the univariate approach consists in the simultaneous variation of all factors and their 
levels over a set of planned experiments and the connection of the results by means of a 
mathematical model [73, 74]. This model is then used for interpretation, prediction and 
optimization. Furthermore, the development of mathematics and applied statistics with 
informatics tools leads to more powerful analysis of data. Consequently the new trends in 
modern research, particularly in analytical chemistry, involve the use of multivariate 
approaches when the experimental domain and the nature of factors are known. Indeed, such 
approaches offer many advantages [74]: 
- reduction of number of experiments; 
- study of numerous factors; 
- computer modeling of the results; 
- detection of interaction effects between the studied factors; 
- better accuracy of the results; 
- optimization of the results and detection of the optimums. 
The methodology of experimental design in method development is supposed to 
guarantee a priori the best quality of information to be derived from the planned experiments. 
Therefore, the choice of the experimental design often depends on the purpose of the study, 
the number of studied factors and their levels and the stage of the method development 
(screening or optimization). Many experimental designs are described in the literature. Even 
though some experimental designs can perform both screening and optimization, the large 
majority can be divided into two groups: screening designs and experimental designs for 
optimization. 
 
I.6.1. Screening designs 
 
The screening designs involve preliminary experiments the purpose of which is to 
isolate the most important factors (k) from amongst large number factors that may affect the 
particularly targeted response(s) [75]. Screening usually involves two level designs, such as 
fractional factorial or Plackett-Burman designs [72] due to the fact that they are simple and 
useful in many applications.  
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Fractional factorial designs are good alternatives to full factorial designs, especially in 
the initial stages of a project and considered as representative subsets of full factorial designs. 
The fractional factorial design is based on the principle that interaction effects could be 
confounded with a main effect. Consequently, the number of experiments (2
k-p
) is reduced by 
a number p which represents the number of two-factor interactions confounded with a main 
effect. However, the result is satisfactory when the interaction effect confounded with a main 
effect remains negligible [47,74]. 
The Plackett-Burman design is a part of a full factorial design 2
k
 which allows 
estimating a first order model with k quantitative or qualitative factors at two levels. The 
number of experiments is at least ≥ k+1 (a multiple of 4) but in case the number of 
experiments is a power of 2, the Plackett-Burman design is equal to a fractional factorial 
design. 
The D-optimal design is an alternative design particularly useful when the researcher 
wants to constrain an experimental region and none of the classical designs is appropriate. 
There are computer-generated designs in which the determinant of the X‟X matrix (an overall 
measure of the information in X) is maximized. Geometrically, this corresponds to maximize 
the volume of X in a k-dimensional space. By choosing N experiments from a candidate set 
that consists of potential experiments, the design can be tailor-made to specific demands 
regarding the desirability of the researcher (experiments and economy constrains for example) 
[76]. Full factorial, fractional factorial and Plackett-Burman designs fulfill the D-optimal 
criteria. 
The experimental matrix is built after selecting the levels of each factor which are 
replaced by (-1), (+1) and possibility (0) for the low level, the high level and the center value, 
respectively. The design evaluation enables the determination of the significant factors to be 
optimized. The decision can be made through the pareto plot or the significance of the 
coefficient of variables defined a priori in the given mathematical model (1) of the screening 
design. 
y = β0+ β1X1 + β2X2+ β3X3 + β12X1X2 + β13X1X3 + β23X2X3 +ε (1) 
where y represents the response, β1, β2
 
et β3  the mains factors, β12, β13  et β23 the coefficients 
of possible two-factor interactions, β0 the intercept et ε the residual error. 
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The pareto plot is an ordered (largest to smallest) histogram displaying percentages of 
variables (factors) in the data with a line graph showing cumulative percentages of the factors. 
Therefore the effects of the factors are visualized and the most important factors can be 
estimated through the line graph.  
The coefficient of a variable should be considered significant when the p-value 
associated is lower than a value fixed a priori (e.g. 5%, value generally admitted). Variables 
that have non significant coefficients are considered as useless and the corresponding effect 
should be neglected in further consideration. 
 
I.6.2. Optimization Designs 
 
For the optimization step, an experimental design supporting the estimation of 
quadratic terms is usually applied in order to further examine the significant factors obtained 
in the screening step. To achieve this purpose, two approaches are proposed in the literature: 
the simplex approach and the response surface methodology (RSM).  
The simplex approach is a stepwise strategy, which means that experiments are 
performed one by one. To maximize the response(s), the first step is to run k+1 experiments 
(k represents the number of variables) to obtain the starting simplex. The yield in each 
corner of the simplex is then analyzed and the corner showing the least desirable result is 
mirrored through the geometrical midpoint of the other corners. In this way a new simplex is 
obtained [76]. The achievement of this approach is to encircle the optimum by means of 
simplex moving into this direction. This approach could lead to a very great number of 
experiments and the risk of not coming close to the optimum depends on its size. Moreover, 
it is not clear at the outset how much resource will be consumed before the purpose is 
reached. To avoid such risks, most analysts prefer the response surface methodology.  
RSMs are multivariate techniques that mathematically fit the experimental domain 
studied in the theoretical design through a response function [77,78]. Two of the most 
common designs generally used for response surface modeling in many applications are the 
central composite and the Box–Behnken designs.  
Central composite designs contain imbedded factorial or fractional factorial designs 
with center points that are augmented with a group of axial (star) points allowing estimation 
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of curvature (cf. fig. 4) [77,78]. These experiments are at a distance α to the center. The value 
of α determines the nature of the central composite design (CCD). For example when α=1, the 
design is called face centered central composite design and the experimental design is cubic. 
Otherwise, α equal 4 k  and all experiments are situated on a sphere with α as the central 
radius. 
The Box–Behnken design is considered an efficient option in RSM and is an ideal 
alternative to central composite designs [76]. It has three levels per factor, but avoids the 
corners of the space, and fills in the combination of center and extreme levels. It combines a 
fractional factorial design with incomplete block designs in such a way as to avoid the 
extreme vertices and to present an approximately rotatable design with only three levels per 
factor. This design is appropriate for situations where the researcher is not interested in 
predicting response at the extremes. 
 
 
 
 
 
 
 
Figure 4. Central composite design (٭star). 
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A less common, but effective method is the Doehlert design. Like the Box–Behnken 
design, Doehlert designs require a lower number of experiments than the central composite 
design (76, 78, 79). Moreover, the Doehlert design compared to the central composite 
approach leads to a higher efficiency value, ultimately determined by dividing the coefficients 
number of the quadratic equation by the number of experiments required for the design [80]. 
Otherwise, a neighboring domain is easily explored by just adding a few experiments [77]. 
 Another design for optimization is a three-level full factorial design particularly useful 
when the number of factors (k) is low (<3) since the number of experiments 3
k
 grows rapidly 
with increasing the number of variables. It is made of the combination of the three levels of 
the k factors that meets the requirement of the maximal determinant. The three-level full 
factorial design also allows the assessment of the quadratic model. 
 The final result is a response surface which is a three dimensional view that may 
provide a clear picture of the response against the most important variables. If the regression 
model displays only main effects (e.i. first order model), the fitted response will be a plane. If 
the model contains interaction effects and/or quadratic effects, the contour lines will be 
curved. The response surface helps the analyst to understand the nature of the relationship 
between two factors and the response. Otherwise, the goodness of the model is often 
evaluated through the R
2
 (explained variability of response) and Q
2
 (explained predicted 
response variability) coefficients. Both coefficients should be close to the unity to express the 
goodness of fit. 
The last step of an analytical procedure remains the validation which has become 
necessary according to legal requirements and quality system within a laboratory. 
 
 
I.7. Analytical method validation 
 
Owing to increasing interdependence among countries during this XXI
st
 century 
globalization, the results of many analytical methods need to be acceptable by everyone. 
Therefore, the use of validated methods has increased to guarantee a common level of quality. 
Actually, in pharmaceutical sciences, the results obtained nowadays with non validated 
methods are considered as meaningless and will not be recognized by regulatory authorities. 
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Consequently, method validation procedures become a subject of great interest for analysts 
and for industrials as well.  
The objective of method validation is to prove that a given quantitative method is able 
to quantify as accurately as possible each of the unknown quantities that the laboratory will 
have to determine. Otherwise, the analyst expects from the validated method that the 
difference between the found result and the unknown “true value” of the sample is small or 
inferior to an acceptance limit (%), a priori specified [81]. These specifications are usually 
admitted by the practice or by the regulatory documents, e.g. 5% for pharmaceutical forms or 
15% for biological samples. 
Over the past two decades, many conferences were held in USA and Europe to 
propose a harmonized procedure for analytical method validation with in mind to minimize 
the risks of accepting a procedure that would not be sufficiently accurate or rejecting a 
procedure that would be valid [82-84]. Regardless of these international conferences, an 
association, such as the “Société Française des Sciences et Techniques Pharmaceutiques” 
(SFSTP), proposed a powerful guide for the validation of quantitative analytical methods. 
This guide has significantly contributed to make a progress in the validation of analytical 
procedures since 1992 [81, 85-89].  
The proposed strategy of validation is based on the use of the accuracy profile 
approach as decision tool, taking into account the new concept of total error (bias + standard 
deviation for intermediate precision) of the procedure [81]. This approach allows obtaining a 
graphical representation, e.g. the accuracy profile, offering an easier visual decision tool 
related to the acceptance limit, for the analyst and other people concerned by the procedure. 
This approach reflects more directly the performance of individual assays and will result in 
fewer rejected in-study runs than the current strategies that compare point estimates of 
observed bias and precision with the targeted acceptance criteria, e.g. 15% for biological 
methods. Indeed, by considering a risk of 5 %, the analyst is able to guarantee that 95 times 
out of 100 the future measurements given by the analytical method will be included in the 
acceptance limits settled according to the requirements. 
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I.7.1. The validation criteria: definitions [81, 82, 87] 
I.7.1.1. Selectivity-specificity 
 
The selectivity of an analytical method is defined as its ability to demonstrate the 
presence of the targeted analyte in a mixture. It is the property of the analytical method to 
exclusively meet the characteristic of the analyte, with the guarantee that the result of the 
analysis is only generated by the analyte. 
 
I.7.1.2. Response function (calibration curve) 
 
The response function of an analytical method is, within the range, the existing 
relationship between the response (signal) and the concentration (quantity) of the analyte in 
the sample. The calibration curve is the simplest monotonous response function. Based on the 
use of the accuracy profile concept, the response function is considered as adequate when the 
accuracy profile is within the acceptance limits fixed a priori over the whole concentration 
range of interest. 
 
I.7.1.3. Linearity  
 
The linearity of an analytical method is its ability, within a given measurement 
interval, to obtain results directly proportional to the quantity (e.g. concentration) in analyte 
within the sample [90]. Therefore, for all series, a regression line was fitted by plotting the 
back-calculated concentrations as a function of the introduced concentrations. This validation 
criterion is required for the evaluation of the trueness, but a linear relationship between 
calculated concentrations and introduced ones does not guarantee the trueness of the 
analytical method. 
 
I.7.1.4. Trueness (bias) 
 
The trueness of an analytical method expresses the closeness of agreement between 
the mean value obtained from a series of measurements and the value which is accepted either 
as a conventional true value or an accepted reference value (international standard, standard 
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from a pharmacopoeia). Trueness can be expressed in terms of recovery and of absolute bias 
or relative bias (systematic error). 
 
I.7.1.5. Precision 
 
The precision of an analytical method expresses the closeness of agreement 
(dispersion level, relative standard deviation (RSD)) between a series of measurements 
obtained from multiple sampling of the same homogeneous sample (independent assays) 
under the prescribed conditions. It gives some information on random errors and it can be 
evaluated at three levels: repeatability, intermediate precision (within the laboratory) and 
reproducibility (between laboratories).  
 
I.7.1.6. Accuracy 
 
The accuracy takes into account the total error, i.e. systematic and random errors, 
related to the test results. Therefore, it is the expression of the sum of the trueness and 
precision. The upper and lower β-expectation tolerance limits expressed as a function of the 
introduced concentrations should not exceed the acceptance limit, e.g. 5% for pharmaceutical 
forms or 15% for biological samples, for all concentration levels tested including the lowest 
concentration level. 
 
I.7.1.7. Limit of detection (LOD) 
 
The limit of detection of an analytical method is the lowest amount of the targeted 
analyte in the sample which can be detected, but not necessarily quantified under the 
experimental conditions prescribed. 
 
I.7.1.8. Limit of quantification (LOQ) 
 
Limit of quantification of an analytical method is the lowest amount of the targeted 
analyte in the sample which can be quantitatively determined under the experimental 
conditions prescribed with a well defined accuracy. 
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I.7.2. Validation phases 
I.7.2.1. Prevalidation phase 
 
Before beginning a validation, some information is needed concerning the dosage 
range, the limit(s) of quantification, the variability of the results and the relevance of the 
regression model retained to be the response function. When experimental designs are applied 
for method development, this information could be provided and the analyst can directly 
switch to the validation process. Otherwise, a prevalidation phase should be performed to 
complete the development of the analytical method. The main objective of this phase is to 
identify the most appropriate response function (linear, non-linear, weighting, data 
transformation), to estimate the limit of quantification, to evaluate the range and the number 
of calibration levels, to determine the analyte recovery and to test method selectivity. 
 
I.7.2.2. Validation phase  
 
The main objective of the validation phase consists in : 
- demonstrating the specificity (selectivity); 
- validating the response function; 
- estimating the precision (repeatability and intermediate precision); 
- estimating the trueness; 
- estimating the accuracy; 
- validating the limit of quantification; 
- validating the concentration range and; 
- assessing the linearity. 
 
I.7.2.3. Decision: the accuracy profile 
 
The accuracy profile, constructed from the tolerance intervals on expected 
measurements, allows deciding the capability or not of an analytical method to give results 
inside the acceptance limits. For a given acceptance limit, the upper and lower β-expectation 
tolerances for total measurement error at σ% level were calculated at each concentration level 
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of the validation standards from the mean relative bias and the standard deviation for 
intermediate precision (cf. Fig.5). 
By using different regression models, several accuracy profiles will be obtained. The 
regression model will be selected according to the accuracy profile which remains within the 
acceptance limits over a larger concentration range with a lower LOQ. The regression models 
that involve results outside the acceptance limits should not be selected.  
 
 
 
 
 
 
 
 
Figure 5. Accuracy profile obtained using a linear regression model after logarithm 
transformation. The plain line is the relative error (%), the dashed lines correspond to the 
accuracy profile i.e. to the β-expectation tolerance limits expressed in relative error, and the 
dotted curves represent the acceptance limits (±10%). 
 
Throughout this thesis, different strategies and concepts described in the present 
introduction for method development, optimization and validation will be used to fulfill the 
objectives which are depicted in the following section. 
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As a result of an intensive advancement in chiral separation technologies, several 
hundreds of chiral stationary phases (CSPs) for liquid chromatography (LC) are now 
commercially available. Among them, polysaccharide-based CSPs have been recognized as 
the most powerful due to their wide scope of application in the field of enantioseparations, 
their stability and their high loading capability. Cellulose and amylose are the most commonly 
used chiral selectors in such polysaccharide-based CSPs. There are the most abundant in the 
nature and interestingly their ester or phenylcarbamate derivatives have shown high chiral 
recognition abilities when coated on silica gel. Moreover, the recognition abilities of cellulose 
phenylcarbamates coated on silica gel can be controlled by the nature and position of the 
substituents on the phenyl groups. Indeed, the cellulose phenylcarbamates with electron-
donating substituents, such as alkyl groups, or/and electron-withdrawing substituents such as 
halogens, exhibit higher chiral recognition than the non-substituted phenyl groups. Three 
cellulose-based CSPs, namely Sepapak-2, Sepapak-4 and Sepapak-5, using cellulose tris(3-
chloro-4-methylphenylcarbamate), cellulose tris(4-chloro-3-methylphenylcarbamate) and 
cellulose tris(3,5-dichlorophenylcarbamate) as chiral selector, respectively, were recently 
commercialized. Although these CSPs have been studied in LC normal phase systems, no 
systematic study of these phases has been performed in polar organic solvent chromatography 
(POSC) which can exhibit alternative recognition mechanisms and some other advantages, 
such as increased solubility for many drug compounds, particularly useful for preparative 
purpose. 
In this thesis the main objective is to evaluate the chiral recognition abilities of these 
three chlorine containing cellulose-based CSPs, Sepapak-2; Sepapak-4 and Sepapak-5, in 
polar organic solvent chromatography. The mobile phase will be made of acetonitrile as the 
main solvent, with basic (0.1% DEA) and acidic additives. Thirteen basic drugs with widely 
different structures and polarities will be selected as model compounds: β-blockers (atenolol, 
betaxolol, celiprolol, metoprolol, oxprenolol, propranolol and sotalol), antimycotics 
(econazole and miconazole) and local anesthetics (bupivacaine, prilocaine and mepivacaine). 
To achieve this goal, we intend first to investigate which factors can influence the 
retention and enantioresolution of these basic compounds on Sepapak-4 by means of a 
univariate approach. In this study, the role of the acidic additive and organic modifier added 
to the mobile phase as well as temperature on retention and enantioresolution will be 
particularly investigated. Afterwards, multivariate screening and optimization strategy will be 
applied. A mathematical model able to predict the enantioresolution of the studied compounds 
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will be developed and a rapid screening strategy for method development using the other 
chlorine containing CSPs will be proposed.  
The second objective is to extend the study of the resolution power of the three CSPs 
using the rapid screening conditions previously defined and to compare the behavior of these 
CSPs in such polar organic mobile phases.  
The third objective is to develop selective, precise, accurate and reliable LC methods 
for the determination of R-ropivacaine in a S-ropivacaine pharmaceutical formulation 
(Naropin
®
, 10 mg/mL solution) and R-amlodipine in a S-amlodipine pharmaceutical 
formulation using one of the studied chlorine containing CSPs in the polar organic solvent 
chromatography mode. Afterwards, these LC methods will be fully validated according to the 
strategy based on the use of accuracy profiles, which takes into account the total error, i.e. the 
estimation of systematic and random errors of measurement results. 
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Summary 
 
A polysaccharide-based chiral stationary phase (Sepapak-4), with cellulose tris(4-
chloro-3-methylphenylcarbamate) as chiral selector, has been investigated in liquid 
chromatography (LC). Its enantioresolution power was evaluated towards 13 basic amino-
drugs with widely different structures and polarities, using polar organic mobile phases. After 
preliminary experiments, acetonitrile was selected as the main mobile phase component, to 
which a low concentration of diethylamine (0.1%) was systematically added in order to obtain 
efficient and symmetrical peaks. Different organic solvents were first added in small 
proportions (5–10%) to acetonitrile to modulate analyte retention. Polar organic modifiers 
were found to decrease retention and enantioresolution while hexane had the opposite effect, 
indicating normal-phase behaviour under these conditions. The addition of an organic acid 
(formic, acetic or trifluoroacetic acid) was found to strongly influence the retention of the 
basic amino drugs in these nonaqueous systems. The nature and proportion of the acidic 
additive in the mobile phase had also deep impact on enantioresolution. Therefore, the studied 
compounds could be subdivided in two groups with respect to the acidic additive used. All 
analytes could be enantioseparated in relatively short analysis times (10-20 min) using these 
LC conditions. 
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III.1. Introduction 
 
Over the last decade, many efforts have been focused on the development of original 
chiral stationary phases (CSPs), either by immobilizing the chiral selector on silica support to 
extend the choice of modifiers or additives in the mobile phase or by proposing new chiral 
selectors.  
Polysaccharide derivatives are the most commonly used CSPs for direct liquid  
chromatographic (LC) enantioseparation of chiral compounds. In particular, the 
phasescomposed of cellulose phenylcarbamate or amylose derivatives as chiral selectors have 
shown a wide range of applications [1–4]. Their enantioresolution ability often depends on the 
structure of the chiral polymers but also on the substituents of the phenyl group in the case of 
phenylcarbamate derivatives [5]. Okamoto and co-workers reported that the derivatives 
having an electron-donating substituent, such as a methyl group in the 3- or 4-positions of the 
phenyl moeity show a high chiral recognition due to the higher order structure of the chiral 
selector adsorbed on silica. Moreover, 3,5-disubstituted phenylcarbamates of cellulose (either 
bymethyl groups or by chloro groups) also showa high enantioresolutionpower [3]. 
Nevertheless, the high solubility of the dichlorophenylcarbamate derivative in organic 
solvents can be problematic. To enhance the chiral recognition, Chankvetadze et al. have 
developed new polysaccharidic CSPs substituted by methyl and chloro groups in positions 3 
and 4 of the phenyl moiety [6–9]. Initially the normal-phase liquid chromatography (NPLC) 
was proposed for all these CSPs. However, it was shown later that not only reversed-phase 
LC (RPLC) with aqueous–organic mobile phases [10–18], but also polar organic solvent 
chromatography (POSC) can be applied [19,20]. 
Since the development of polysaccharides-based CSPs by Okamoto and co-workers 
[3,5,21–23] and the commercialization of derivatives, only a few efforts have been focused on 
the study of the effects of factors, such as the acidic additives, which can play acrucial role in 
polar organic solvent chromatography with respect to chiral selectivity. To the best of our 
knowledge, although some previous studies have shown the role of basic and acidic additives 
for enantioseparation in NPLC [24–26], only few systematic comparative studies have been 
reported in POSC concerning the use of polysaccharides-based CSPs with different acidic 
additives for separation of enantiomers [20,27].  
  Chapter III. 
50 
In the present study, the chiral recognition ability of a polysaccharide-based CSP with 
cellulose tris(4-chloro-3-methylphenylcarbamate) as chiral selector (cf. Fig. 1A), namely 
Sepapak-4, was evaluated for the enantioseparation of 13 basic amino-drugs with widely 
different structures and polarities (cf. Fig. 1B). Acetonitrile was used as main solvent with 
basic and acidic additives in POSC. The effect of factors likely to influence the 
chromatographic parameters such as retention, selectivity and enantioresolution on Sepapak-
4, was examined. 
 
 
III.2. Experimental 
III.2.1. Chemicals and reagents 
 
Acebutolol hydrochloride, metoprolol tartrate, oxprenolol hydrochloride, propranolol 
hydrochloride, econazole nitrate andprilocaine hydrochloride were supplied by Sigma–
Aldrich (Saint-Louis, MO, USA). Celiprolol hydrochloride was provided by Rorer (Brussels, 
Belgium), miconazole nitrate by Janssen Pharmaceutica (Beerse, Belgium), sotalol 
hydrochloride by Profarmaco Combrex (Milan, Italy), atenolol by Erregierre (Bergamo, 
Italy), betaxolol by LERS (Paris, France), bupivacaine hydrochloride by Astra Pharmaceutical 
Products (Södertalje, Sweden) and mepivacaine hydrochloride by Federa (Brussels, Belgium). 
All samples are racemates used without further purification. 
Acetonitrile (ACN), methanol, ethanol and 2-propanol of HPLC grade and glacial 
acetic acid (AcA) pro analysi were provided by Merck (Darmstadt, Germany). Trifluoroacetic 
acid (TFA), diethylamine (DEA) and formic acid (FA) pro analysi were obtained from Acros 
Organics (Geel, Belgium) and n-hexane from BDH Hypersol (Poole, UK). 
 
 
III.2.2. Instrumentation 
 
The chromatographic system from Agilent Technologies (Waldbronn, Germany) 
consisted in a binary pump, a thermostated column compartment, a diode array detector and 
an automatic injector, all of 1100 series. The Chemstation software was used for system 
control and data acquisition.
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Figure. 1. Structure of Sepapak-4 chiral selector (a) and molecular structures of the studied 
basic amino drugs (b). 
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The chiral column Sepapak-4 (250mm×4.6mm I.D.) was kindly provided by 
Sepaserve (Münster, Germany). The chiral selector adsorbed on aminopropylsilanized silica 
(nominal particle size 5µm and nominal pore diameter 100 nm) was cellulose tris(4-chloro-3-
methylphenylcarbamate) in the amount of 25% (w/w). 
 
 
III.2.3. Solutions for method development 
 
The mobile phases used of the different experiments were prepared by mixing the 
required proportions of acetonitrile, organic modifier (methanol or hexane) and acidic 
additives (TFA; FA; AcA). Then 0.1% of DEA (9.7 mM) was systematically added. 
Analytical solutions of racemate compounds of nearly 100 µg/ml were prepared by dissolving 
the appropriate amount of the substance in the required volume of mobile phase. 
 
 
III.2.4. Chromatographic conditions 
 
The mobile phases consisted in amixture of acetonitrile, organic modifier (methanol or 
hexane), acidic additive and DEA (v/v) and were pumped at a constant flow-rate of 1.0mL 
min−1. In the different experiments, the DEA percentage in the mobile phase was settled at 
0.1%. The injection volume was 20µL. The analytes were detected photometrically at 220 
nm. 
 
 
III.3. Results and discussion 
 
Originally dedicated for normal- and reversed-phases, polysaccharidic CSPs provided 
good results in POSC [19, 28–32]. In this system, only polar organic solvents such as 
acetonitrile, methanol, 2-propanol and their mixtures are used. Methanol and acetonitrile were 
tested as the main component of the mobile phase and the best results were obtained with 
acetonitrile. These results confirm observations made by others [29]. Therefore, acetonitrile 
was selected as the main solvent. 
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In addition to the classical factors such as temperature, pH and type of organic 
modifier, which can influence the enantioseparation in LC, several authors demonstrated that 
the acidic and basic mobile phase additives can also have a significant impact [20,24,33,34]. 
In these studies mostly carried out in normal-phase, these additives were supposed to 
minimize the non-specific interactions between the analytes and the free silanol groups of the 
CSP. Nevertheless, these additives are known to have a strong affinity for the CSP 
[20,24,33,34]. Therefore, the present study protocol includes a rinsing procedure with neat 
acetonitrile for 1 h followed by an equilibration of the CSP with the mobile phase containing 
both acidic and basic additives for 1 h. 
Since few information on the behaviour of Sepapak-4 in POSC is available, this 
screening study was conducted following a classical method development. In accordance with 
the literature, the studied factors are those commonly investigated, namely the temperature, 
the nature and the proportion of the organic modifier as well as the acidic additive. It has been 
checked that the nature of the basic additive, namely diethyamine, triethylamine and 
butylamine, had no significant influence on enantioresolution, as already observed in the 
literature for polysaccharide based CSP [20]. 
 
 
III.3.1. Effect of the temperature 
 
The influence of the temperature on the enantioresolution (Rs) of the studied chiral 
drugs was investigated (cf. Fig. 2). As can be seen in this figure, the change in 
enantioresolution with temperature seems to be generally rather limited and very much 
compound dependent. For those which exhibited an increased enantioresolution with 
temperature, a significant efficiency enhancement was observed at 35°C (e.g. for celiprolol, 
plate number (N) increases from 3200 at 15°C to 6500 at 35°C). The latter effect seems to be 
mainly responsible for the observed improvement in resolution. However, for three 
compounds with low enantioresolution (namely, mepivacaine, oxprenolol and metoprolol (cf. 
Fig. 2), high temperature is defavourable. Finally, it was decided to select 15°C for further 
investigations. 
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Figure. 2. Influence of the temperature on enantioresolution.  
Mobile phase: ACN/0.1%DEA/0.1% TFA; temperature: 15, 25 and 35°C.  
Other conditions: see Section 2. 
 
 
III.3.2. Effect of the addition of an organic modifier 
 
As illustrated in Fig. 3 for atenolol enantiomers, the addition of 10% hexane in the 
mobile phase increased the retention and the enantioresolution of most of the studied 
molecules, unlike methanol, confirming the involvement of hydrogen-bond interactions 
between the analyte and the chiral selector. Therefore, these results clearly show that a polar 
organic modifier increases the elution capacity of the mobile phase, in accordance with 
Lyman and Stringham‟s work [32], indicating a normal-phase behaviour where the hydrogen-
bond interactions are regulated by the nature and the proportion of the organic modifier. 
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Figure. 3. Chromatograms illustrating the effect of n-hexane or methanol addition 
in the mobile phase on atenolol enantiomers resolution. 
Mobile phase: ACN/0.1%DEA/0.1% TFA/x (0% or 10%) hexane or methanol; 
 temperature: 15°C. Other conditions: see Section 2. 
 
 
III.3.3. Effect of the nature of the acidic additive 
 
The importance of the nature of the acidic additive was also demonstrated. Table 1 
presents the retention factor, the enantioresolution and selectivity values obtained in the 
presence of 0.1% TFA (13.5 mM), acetic acid (26.5 mM) and formic acid (17.5 mM). As can 
be seen in this table, the enantiomers of propranolol, sotalol, miconazole and bupivacaine 
were not resolved when TFA was used as an acidic modifier, while a complete 
enantioseparation was observed in the presence of formic acid and/or acetic acid. The best 
enantioresolution of the β-blockers (except for oxprenolol, propranolol and sotalol) and 
prilocaine was obtained with TFA while the best results for the imidazole derivatives 
(econazole and miconazole) and sotalol were observed with acetic acid. As for the other local 
anaesthetics (bupivacaine and mepivacaine), oxprenolol and propranolol, formic acid gave 
rise to the highest Rs values. Moreover, this acid led to the strongest retention for all studied 
compounds, which indicates that the acidic character of the additive is not the only factor 
decreasing retention. Indeed, formic acid is stronger than acetic acid but gives rise to higher 
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retention. Obviously, other factors intervene in the interactions between the analytes and the 
CSP such as possibly ion-pair formation which is in principle stronger for acetic acid than 
formic acid. Results from Table 1 clearly show that acidic additives have also an important 
effect on enantioresolution and selectivity by contrast to data obtained with classical cellulose 
or amylose tris(3,5-dimethylphenylcarbamate) based CSP [33]. Therefore, it can be assumed 
that the introduction of chlorine on the phenyl moiety of Sepapak-4 has a deep impact on the 
ability of acidic additives to enhance enantioresolution. This might be explained by a 
reduction of non-specific interactions with the CSP due to the presence of acidic additive in 
the mobile phase [24,33,34]. 
 
 
III.3.4. Effect of the proportion of the acidic additive 
 
Fig. 4 illustrates the influence of the proportion of acetic and formic acids on the 
retention factor. Since all compounds of the same class exhibited similar behavior, only the 
results obtained for one compound of each class is presented in Fig. 4. It is worth noting that 
the percentage of TFA was not investigated since proportions lower or higher than 0.1% led 
to a very unstable baseline and to a very low retention. As can be seen in Fig. 4, similar 
effects were observed for the two acidic additives but the influence of acetic acid 
concentration seems to be less pronounced. A tendency to an increase in retention with the 
acidic additive content was found for most compounds and seems to be related to their basic 
character, since only the two analytes with low pKa values, namely the two imidazole 
derivatives, showed an opposite trend. 
Tables 2 and 3 present the effect of acetic and formic acids proportion in the mobile 
phase on the enantioresolution and selectivity values of the studied basic drugs. As can be 
seen in these tables, the influence of the acidic additive concentration on enantioresolution 
and selectivity seems to follow the same trend as observed for retention (cf. Fig. 4). In most 
cases, Rs and selectivity values were found to increase with acidic additive percentage, except 
for acetic acid which shows an opposite effect (cf. Tables 1–3). By contrast, a significant 
decrease in enantioresolution and selectivity was obtained for the two less basic compounds 
(i.e. the imidazole derivatives). 
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Fig. 4. Inﬂuence of the acetic (A) and formic (B) acid proportion in the mobile phase on the 
retention factor (k’1). 
Mobile phase: ACN/0.1% DEA/(0.05–0.3%) AcA (A) or  
ACN/0.1% DEA/(0.015–0.3%) FA (B); temperature: 15°C. 
Other conditions: see Section 2 
 
(A) 
(B) 
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Table 1. Influence of the acidic additive nature in the mobile phase on the retention factor 
(k’1), the enantioresolution (Rs) and selectivity (α) of the studied basic amino-drugs using 
Sepapak-4. 
  
  
0.1% TFA 0.1% AcA 0.1% FA 
k'1 Rs α k'1 Rs α k'1 Rs α 
Acebutolol 1.50 0.92 1.09 / / / / / / 
Atenolol 5.1 4.9 1.42 / / / / / / 
Betaxolol 0.55 2.3 1.34 5.4 1.13 1.09 13.8 - - 
Celiprolol 2.2 2.7 1.31 / / / / / / 
Metoprolol 0.48 1.71 1.26 5.0 0.77 1.06 12.4 - - 
Oxprenolol 0.38 1.14 1.20 3.7 2.2 1.17 9.6 2.3 1.16 
Propranolol 0.28 - - 4.6 1.20 1.08 12.3 2.2 1.15 
Sotalol 0.16 - - 4,1 1.85 1.16 12.0 1.50 1.11 
Econazole 1.31 1.10 1.10 3.0 6.4 1.55 4.1 6.1 1.48 
Miconazole 1.90 - - 4.3 3.9 1.29 5.7 2.7 1.19 
Bupivacaine 0.72 - - 0.62 - - 2.8 2.6 1.19 
Mepivacaine 0.64 1.35 1.16 0.65 1.21 1.19 2.6 2.5 1.19 
Prilocaine 0.55 9.3 2.7 0.29 1.82 1.36 1.85 1.22 1.09 
 „/‟ no peak obtained within 60 min. „–‟ no enantioresolution observed. Mobile phase: 
ACN/0.1% DEA/0.1% (TFA: 13.5 mM, AcA: 26.5 mM or FA: 17.5 mM); temperature: 15°C; 
other conditions: see Section 2. Bold values: highest Rs values obtained for each analyte. 
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Table 2. Influence of acetic acid proportion in the mobile phase on the enantioresolution (Rs) 
and selectivity (α) of the studied basic amino-drugs using Sepapak-4. 
 
Acetic acid (%) 
0.05
a
 0.1
b
 0.2
c
 0.3
d
 
Rs α Rs α Rs α Rs α 
Acebutolol / / / / / / / / 
Atenolol / / / / / / / / 
Betaxolol 1.56 1.11 1.31 1.09 1.46 1.10 0.89 1.06 
Celiprolol / / / / / / / / 
Metoprolol 1.08 1.07 0.80 1.06 0.80 1.06 - - 
Oxprenolol 2.3 1.17 2.2 1.17 2.4 1.17 1.98 1.42 
Propranolol 0.95 1.07 1.20 1.11 1.54 1.11 2.1 1.15 
Sotalol 1.93 1.17 1.85 1.15 1.89 1.15 1.50 1.13 
Econazole 6.7 1.53 6.4 1.51 6.1 1.51 5.8 1.50 
Miconazole 3.9 1.30 3.9 1.26 3.6 1.26 3.4 1.25 
Bupivacaine - - - - - - - - 
Mepivacaine 1.35 1.14 1.21 1.11 1.20 1.11 1.20 1.12 
Prilocaine 2.2 1.35 1.82 1.14 1.38 1.14 - - 
 „/‟ no peak obtained within 60 min. „–‟ no enantioresolution observed. Mobile phase: 
ACN/0.1% DEA/(0.05–0.3)% AcA; temperature: 15°C; other conditions: see Section 2. 
a,b,c,d
 letters refer to molar concentrations of acidic additives: (a) 8.7 mM; (b) 17.5 mM; (c) 35 
mM; (d) 52.5 mM. 
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Table 3: Influence of formic acid proportion in the mobile phase on the enantioresolution (Rs) 
and selectivity (α) of the studied basic drugs on Sepapak-4. 
 
Formic acid (%) 
0.015
a
 0.05
b
 0.1
c
 0.2
d
 0.3
e
 
Rs α Rs α Rs α Rs α Rs α 
Acebutolol - - / / / / / / 1.32 1.09 
Atenolol / / / / / / / / / / 
Betaxolol - - - - - - 0.6 1.05 / / 
Celiprolol / / / / / / / / - - 
Metoprolol - - - - - - - 1 - - 
Oxprenolol 1.53 1.12 1.68 1.11 2.3 1.16 2.4 1.16 2.4 1.15 
Propranolol 1.62 1.12 1.82 1.12 2.2 1.15 2.3 1.16 2.3 1.16 
Sotalol 0.77 1.07 1.01 1.07 1.5 1.11 1.6 1.12 1.57 1.10 
Econazole 7.7 1.59 7.0 1.58 6.1 1.48 3.7 1.28 2.6 1.16 
Miconazole 3.9 1.24 3.2 1.23 2.7 1.19 1.39 1.09 - - 
Bupivacaine - - - - 2.6 1.19 3.2 1.22 2.9 1.18 
Mepivacaine 1.49 1.14 1.28 1.14 2.5 1.19 2.9 1.21 3.3 1.27 
Prilocaine 2.9 1.34 1.75 1.21 1.22 1.09 1.09 1.21 2.7 1.27 
„/‟ no peak obtained after 60 min. „–‟ no enantioresolution observed.  
Mobile phase: ACN/0.1% DEA/(0.015–0.3)% FA; temperature: 15°C; other conditions: see 
Section 2.  
a,b,c,d,e
: letters refer to molar concentration of acidic additives: (a) 4 mM; (b) 13.2 mM; (c) 26.5 
mM; (d) 53 mM; (e) 79.5 mM. 
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The chromatograms illustrated in Fig. 5 show that an increase of the formic acid 
concentration in the mobile phase gives rise to a decrease of the econazole retention and 
enantioresolution whereas the opposite trend is observed for the more basic mepivacaine. It is 
worth noting that higher concentrations (>0.2%) are not recommended because they have a 
tendency to give rise to noisy baseline. 
Therefore, two groups of substances could be distinguished from Tables 1–3, 
according to the acidic additive used. The first group is constituted of atenolol, celiprolol, 
acebutolol, betaxolol, metoprolol and prilocaine. For these compounds, TFA gives rise to the 
best enantioresolution. The second group includes the other compounds, i.e. bupivacaine, 
mepivacaine, econazole, miconazole oxprenolol, propranolol and sotalol for which a high 
enantiomeric separation is observed with formic acid. 
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Figure. 5. Chromatograms of econazole (A) and mepivacaine (B) enantiomers illustrating the 
effect of formic acid proportion on enantioresolution. 
Mobile phase: ACN/0.1% DEA/ (0.02–0.2%) FA; temperature: 15°C. Other conditions: see 
Section 2. 
 
 
III.4. Conclusion 
 
The newly commercialized chiral stationary phase Sepapak-4 was tested with 
acetonitrile as main mobile phase component and 0.1% of basic additive (DEA). The results 
showed a significant effect of acidic additive nature and concentration on retention, selectivity 
and enantioresolution of the basic chiral compounds. The studied CSP demonstrated good 
chiral discrimination ability. Temperature, the type and concentration of the acidic additive as 
well as the presence of an organic modifier in the mobile phase were found to be important 
parameters to optimize retention and enantioresolution. Furthermore, the tested compounds 
showed different behaviours and can be classified in two groups according to the acidic 
additive selected. These results will be exploited to perform multivariate screening and 
optimization of enantioresolution on this CSP. 
 
(B) (A) 
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Summary 
 
The resolving power of a new commercial polysaccharide-based chiral stationary 
phase (CSP), Sepapak-4, with cellulose tris(4-chloro-3-methylphenylcarbamate) coated on 
silica microparticles as chiral selector, was evaluated towards the enantioseparation of ten 
basic drugs with widely different structures and hydrophobic properties, using acetonitrile as 
the main component of the mobile phase. A multivariate approach (experimental design) was 
used to screen the factors (temperature, n-hexane content, acidic and basic additives) likely to 
influence enantioresolution. Then the optimization was performed using a face-centered 
central composite design. Complete enantioseparation could be obtained for almost all tested 
chiral compounds, demonstrating the high chiral discrimination ability of this CSP using polar 
organic mobile phases made up of acetonitrile and containing an acidic additive 
(trifluoroacetic or formic acid), 0.1% diethylamine and n-hexane. These results clearly 
illustrate the key role of the nature of the acidic additive in the mobile phase. 
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IV.1. Introduction 
 
The use of chiral stationary phases (CSPs) in liquid chromatography (LC) has 
increased dramatically in the last two decades [1, 2]. This is not only related to the common 
availability and demonstrated success of LC instrumentation for performing separations in the 
pharmaceutical industry but also because CSPs can be used in LC both for analytical and 
preparative chiral separations in a very efficient and flexible way [3].  
Among the large number of commercially available CSPs, polysaccharide derivatives 
belong to the most widely used phases for LC enantioseparations [4, 5]. Many derivatives 
(acetate, benzoates, carbamates, etc) of polysaccharides such as cellulose [6-9] and amylose 
[6, 8] have shown particularly high chiral recognition ability for a wide variety of racemates 
including many drugs [10-16]. This recognition ability not only depends on the nature [17-22] 
and position of substituents introduced on the phenyl groups of the carbamates derivatives [7] 
but also on the composition of the mobile phase used and the presence of acidic additives [17; 
23-25].  
To enhance the chiral recognition ability of polysaccharide based CSPs, new 
phenylcarbamate derivatives were developed [18-22]. The latter have both an electro-donating 
methyl group and an electro-withdrawing chloro or fluoro group on the phenyl moiety. These 
newly commercialised CSPs have shown very high chiral recognition ability [18-22, 26-28], 
which make them possible alternative to well known CSPs based on 3,5-
dimethylphenylcarbamate of cellulose and amylose [25,29-32]. The traditional mobile phase 
for polysaccharide based CSPs has been an alcohol-alkane combination. Unfortunately, many 
pharmaceutical compounds have poor solubility in this kind of mobile phase [33]. The 
reversed phase mode can cover many potential HPLC applications of those polysaccharide 
based CSPs [34-43]. Nevertheless the polar organic mode has become increasingly popular 
during last decade [40-45]. In fact, polar organic eluents offer the advantages of alternative 
chiral recognition mechanisms, higher solubility for many analytes and easier removal from 
the analytes [44]. These advantages are particularly interesting in preparative scale 
enantioseparation or simulating moving bed (SMB) chromatography as the loading capacity 
strictly depends on sample solubility in eluents [44]. 
In the present work, the resolving power of the recently commercialized 
polysaccharide based chiral stationary phase (CSP), Sepapak-4, with cellulose tris (4-chloro-
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3-methylphenylcarbamate) as chiral selector, has been evaluated toward the enantioseparation 
of ten basic drugs with widely different structures and hydrophobic properties (Fig.1), using 
acetonitrile as the main mobile phase component. To achieve this goal, a screening 
experimental design, namely a fractional factorial design, has been applied to deduce the main 
factor influencing on enantioresolution in these LC systems. Then, a face-centered central 
composite design has been used to obtain optimal LC conditions for the enantioresolution of 
these ten chiral basic drugs. Finally, a strategy for rapid method development has been 
proposed. 
 
 
IV.2. Experimental 
IV.2.1. Chemicals and reagents 
 
Acebutolol, oxprenolol, propranolol and prilocaine hydrochlorides, metoprolol 
tartrate, terbutaline hemisulfate, alprenolol, pindolol and econazole, isoconazole and 
sulconazole nitrates were supplied by Sigma-Aldrich (Saint-Louis, MO, USA). Celiprolol 
hydrochloride was provided by Rorer (Brussels, Belgium), miconazole nitrate by Janssen 
Pharmaceutica (Beerse, Belgium), sotalol hydrochloride by Profarmaco Combrex (Milan, 
Italy), atenolol by Erregierre (Bergamo, Italy), betaxolol by LERS (Paris, France), 
bupivacaine hydrochloride by Astra Pharmaceutical Products (Södertalje, Sweden) and 
mepivacaine hydrochloride by Federa (Brussels, Belgium). All samples were racemates used 
without further purification. 
 Acetonitrile (ACN) of HPLC grade and glacial acetic acid (AcA) pro analysi were 
provided by Merck (Darmstadt, Germany). Trifluoroacetic acid (TFA), diethylamine (DEA), 
and formic acid (FA) pro analysi were obtained from Acros Organics (Geel, Belgium). 
Triethylamine (TEA) pro analysi was provided from Sigma-Aldrich (St Louis, USA), 
butylamine (BuA) pro analysi from Fluka (Buchs, Switzeland) and n-hexane of HPLC grade 
from BDH Hypersol (Poole, UK). 
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Figure 1. Structure of studied basic drugs. 
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IV.2.2. Instrumentation 
 
The chromatographic system from Agilent Technologies (Waldbronn, Germany) 
consisted of a binary pump, a thermostated column compartment, a diode array detector and 
an automatic injector, all of 1100 series. The Chemstation software was used for system 
control and data acquisition.  
The chiral column Sepapak-4 (250 mm x 4.6 mm I.D.) was kindly provided by 
Sepaserve GmbH (Münster, Germany). The chiral selector cellulose tris(4-chloro-3-
methylphenylcarbamate) was coated on pretreated  aminopropylsilanized silica (with nominal 
particle size 5 µm). 
The experimental design and the statistical calculations were performed using the 
MODDE software version 6.0 from Umetri AB (Umeä, Sweden). 
 
 
IV.2.3. Solutions for method development 
 
Analytical solutions of racemic compounds of 100 µg/ml were prepared by dissolving 
the appropriate amount of the substance in the required volume of mobile phase. 
 
 
IV.2.4. Chromatographic conditions 
 
The mobile phases consisted of a mixture of acetonitrile, organic modifier (hexane), 
acidic additive and basic additive (v/v) and were pumped at a constant flow-rate of 1.0 
mL.min-1. In all experiments, the basic additive percentage in the mobile phase was settled at 
0.1 %. The injection volume was 20 µL. The analytes were detected photometrically at 220 
nm. The repeatability of the main response (enantioresolution), was evaluated using standard 
deviation (SD), calculated from four independent injections of atenolol. This SD was lower 
than 0.1. 
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IV.3. Results and discussion 
 
In our previous work dealing with the screening of the factors likely to influence the 
enantioresolution of thirteen chiral basic pharmaceuticals, temperature, the nature of the 
acidic additive and of the organic modifier in the mobile phase were selected as important 
factors after an univariate screening study [25]. In this previous study, 0.1% DEA was 
systematically added to the mobile phase as basic additive.  
In the present work, we evaluated the effect of three basic additives namely the 
primary amine butylamine (BuA), the secondary amine diethylamine (DEA) and the tertiary 
amine triethylamine (TEA). They were added to the previously studied factors for the 
multivariate optimization. This optimization procedure was divided into two steps: (a) 
multivariate screening to select the most important factors likely to influence the 
enantioresolution of the studied compounds; (b) multivariate optimization to obtain 
chromatographic conditions for maximum enantioresolution. Preliminary experiments were 
performed to ensure that no reversal in the elution order of enantiomers occurred. Each 
racemic mixture of propranolol and bupivacaine was spiked with one of the two enantiomers 
and no reversal of the elution order of enantiomers was observed under variation of 
temperature or acidic additive concentration.  
The screening was carried out with ten chiral drugs, namely betaxolol, metoprolol, 
oxprenolol, propranolol, sotalol, econazole, miconazole, bupivacaine, mepivacaine and 
prilocaine. 
 
 
IV.3.1. Screening design 
 
To achieve the multivariate screening aiming to deduce the most important factors, a 
fractional factorial design was applied to four factors (two quantitative factors and two 
qualitative factors), namely the n-hexane proportion (0-10%), the temperature (15-35°C), the 
nature of the acidic additive (TFA, FA and AcA) and the nature of the basic additive (DEA, 
TEA and BuA), with three level each. This design involved 9 experimental points with 3 
replicates in the center of the domain resulting in 12 randomized runs (Table 1). To define the 
relationship between the response and the factors, a linear regression model was applied on 
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the basis of a multiple linear regression (MLR). The selected model included 6 coefficients as 
indicated in the equation (1) 
y = β0 + β1X1 + β2X2 + β3X3 + β4X4 + ε (1) 
where y is the enantiomeric resolution, β1, β2, β3 and β4 the main effects, β0 the intercept and ε 
the error term. 
X1 is the organic modifier percentage (0-10 %; n-hexane); X2 is the temperature (15-35°C); 
X3 is the acidic additive (0.1 % of TFA, AcA or FA); X4 is the basic additive (0.1% of DEA, 
TEA or BuA). 
Table 2 presents the different coefficients of the screening model and their statistical 
significance for the ten compounds studied. The effect of a factor is considered as significant 
if its p-value is lower than 0.05. The p-value is the probability of getting a result as extreme or 
more extreme than the one observed if the proposed null hypothese is correct. In this study, 
only positive effects were taken into account in order to maximize enantioresolution. 
As can be seen in this table, temperature has no significant effect on enantioresolution 
for the studied compounds except sotalol. An increase of hexane proportion in the mobile 
phase influenced enantioresolution of bupivacaine, econazole and propranolol. Regarding the 
nature of the acidic additive, it is worth noting that TFA has a significant effect on resolution 
of betaxolol, metoprolol and prilocaine enantiomers. On the other hand, enantioresolution of 
bupivacaine, econazole, miconazole oxprenolol, propanolol and sotalol is significatively 
influenced by FA. Finally, AcA has a significant effect on the enantioresolution of econazole, 
miconazole and sotalol. 
Enantioresolution was slightly influenced by basic additives: the effect of DEA was 
positive and significant for econazole, prilocaine, and propranolol enantiomers whereas BuA 
had a significant positive effect on enantioresolution of metoprolol and sotalol. For 
bupivacaine, the best basic additive was TEA. 
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Table 1. Screening design. 
Trial Factors 
X1 X2 X3 X4 
1 0 15 TFA DEA 
2 0 25 AcA TEA 
3 0 35 FA BuA 
4 5 15 AcA BuA 
5 5 25 FA DEA 
6 5 35 TFA TEA 
7 10 15 FA TEA 
8 10 25 TFA BuA 
9 10 35 AcA DEA 
10 5 25 TFA DEA 
11 5 25 TFA DEA 
12 5 25 TFA DEA 
X1 is hexane proportion in the mobile phase; X2 is temperature of the CSP; X3 is the nature of 
the acidic additive (0.1%) in the mobile phase (TFA: trifluoroacetic acid; FA: formic acid and 
AcA: acetic acid); X4 is the nature of the basic additive (0.1%) (BuA: butylamine; DEA: 
diethylamine and TEA: triethylamine). 
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Table 2. Coefficients (Coef.) of the model and their p-values. 
 Betaxolol Metoprolol Prilocaine Propranolol Oxprenolol 
Coef. 
p-
value 
Coef. 
p-
value 
Coef. p-value Coef. p-value Coef. p-value 
β1hexan -0.362 0.1967 -0.238 0.1748 -0.46 0.1013 0.344 0.0212 0.318 0.1031 
β2 temp 0.192 0.3620 0.088 0.4867 -0.45 0.1091 0.003 0.9666 0.008 0.9482 
β3 TFA 0.667 0.0287 0.47 0.0189 4.450 <0.0001 -0.92 0.0003 -0.52 0.0148 
β3 AcA 0.022 0.9405 0.075 0.6801 -1.94 0.0007 -0.34 0.0338 -0.26 0.2189 
β3 FA -0.688 0.0422 -0.545 0.0197 -2.51 0.0002 1.269 0.0002 0.786 0.0065 
β4 DEA 0.007 0.9749 -0.077 0.5680 0.64 0.0394 0.241 0.0391 0.301 0.0794 
β4 TEA -0.295 0.3406 -0.335 0.1184 -0.49 0.1184 0.103 0.3992 -0.03 0.8722 
β4 BuA 0.288 0.2849 0.412 0.0466 -0.15 0.5788 -0.34 0.0212 -0.27 0.1470 
 
 
Sotalol Econazole Miconazole Bupivacaine Mepivacaine 
Coef. p-value Coef. p-value Coef. p-value Coef. p-value Coef. p-value 
β1hexane -0.058 0.0049 0.4062 0.0121 0.1361 0.3687 0.3095 <0.0001 0.2674 0.2755 
β2Temp 0.081 0.0006 0.0200 0.8013 0.2567 0.0751 -0.3117 <0.0001 -0.3800 0.0878 
β3 TFA -1.2 <0.0001 -2.802 <0.0001 -1.5886 0.0002 -0.7219 <0.0001 -0.4538 0.0659 
β3 AcA 0.735 <0.0001 1.2014 0.0004 1.1348 0.0019 -0.7219 <0.0001 -0.0788 0.7660 
β3 FA 0.465 <0.0001 1.6004 <0.0001 0.4538 0.0279 1.4438 <0.0001 0.5326 0.0658 
β4 DEA 0.023 0.0572 0.2247 0.0475 0.0581 0.6393 -0.0086 0.2746 0.1162 0.5552 
β4 TEA -0.082 0.0025 -0.148 0.2441 -0.1086 0.5276 0.3181 <0.0001 -0.1955 0.4737 
β4 BuA 0.0583 0.0049 -0.076 0.4597 0.0505 0.7266 -0.3095 <0.0001 0.0793 0.7272 
(a) Values significant at the 5% level are printed in bold 
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However it should be noted that among these basic additives only DEA had a positive 
effect in most cases (8/10) even if this effect was significant only for three of the ten 
compounds studied. Therefore, to simplify the study, DEA was selected as basic additive for 
further experiments. 
From those results, the studied drugs could be divided in two groups: (i) group I, 
including betaxolol, metoprolol and prilocaine, for which only one factor  is significant, i.e. 
the nature of the acidic additive: TFA being the only additive with a favourable effect on 
enantioresolution; (ii) group II, containing bupivacaine, econazole , miconazole, oxprenolol, 
propanolol and sotalol, with two significant factors: the nature of the acidic additive (FA 
being the most useful additive in this case) and the proportion of n-hexane in the mobile 
phase. On the other hand, no factor was found significant for mepivacaine enantioresolution, 
even if the best resolution value (2.5) was observed with FA.  
Since the nature of acidic additive is the only factor likely to influence significantly 
the enantioresolution in group I, there is no need to perform further optimization since a 
proportion lower than 0.1% TFA led to a very unstable baseline while a TFA concentration 
higher than 0.1% gave rise to a very low retention [25]. Therefore the best conditions for 
enantioresolution generated from the screening were applied and the observed results were 
found to be close to those predicted (cf. Table 3). For mepivacaine, 0.1% FA was selected as 
acid additive, together with the central value of the n-hexane proportion (5%). The 
corresponding chromatograms are presented in Fig.2.  
As demonstrated earlier, the proportion of acidic additive in the mobile phase often 
has a significant influence on the enantioresolution of basic drugs using this kind of 
polysaccharidic stationary phase. The optimization of enantioresolution for compounds of 
group II was therefore carried out with two quantitative factors, namely the formic acid (FA) 
proportion (0.015-0.3%) according to results obtained in our previous study [25] and the n-
hexane proportion (0-10%) in the mobile phase. The temperature was held at 25°C, central 
value in the screening design, and the basic additive selected was DEA (0.1%). 
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Table 3. Highest enantioresolution values (Rs) obtained from screening experiments. 
Analytes Mobile phase 
RT (peak 2) 
(min) 
Rs 
Predicted 
(confidence 
interval at 95%) 
Observed 
Betaxolol 
(a) 
5.2 2.3 [1.46-3.12] 2.1 
Metoprolol 4.9 1.64 [1.12-2.15] 1.5 
Prilocaine 7.0 9.2 [8.27-10.1] 8.6 
Mepivacaine (b) 10.3 2.4 [1.32-3.48] 2.4 
Mobile phases: (a) ACN/0.1% DEA/0.1% TFA; (b) ACN/0.1% DEA/0.1% FA/5% hexane; 
Temperature: 25°C; Other conditions: see Experimental. 
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Figure 2. Chromatograms obtained under the best screening conditions. 
Prilocaine; B) Betaxolol; C) Metoprolol; D) Mepivacaine. 
Mobile phase: Figs A to C: ACN/ 0.1% DEA/0.1%TFA ; Fig D: ACN/ 0.1% DEA/0.1%FA/ 
5% hexane; temperature : 25°C; Other conditions: see Experimental and Table 3. 
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IV.3.2. Optimization  
 
The optimization of the selected quantitative factors was performed using a face-
centered central composite design (FCCD) with 8 experimental points and three replicates in 
the center resulting in 11 randomized runs. It was necessary to select three levels for each 
factor in order to estimate the quadratic effects. For that purpose a quadratic regression model 
was applied in order to observe possible quadratic and interactions effects besides the main 
effects. The model was assumed to be expressed by the following second order polynomial 
equation: 
y = β0 + β1X1 + β2X2 + β11X1
2
 + β22X2
2
 + β12X1X2 + ε  
where y is enantiomeric resolution; β1 and β2 (coefficients of linear effects), β11 and β22 
(coefficients of quadratic effects), β12 (coefficient of interaction effect), β0 ( intercept) and ε 
(error term) are the different coefficients of the model; X1 and X2 are the levels of factors. 
The quality of fit of the model was assessed by the coefficient of determination (R
2
) 
which is the fraction of response variation explained by the model and the plot of residuals. 
All values of R
2
 obtained were above 0.98, which demonstrated the quality of fit. The fraction 
of the variation of the resolution that can be predicted by the model, namely Q
2
, remained 
higher than 0.86, meaning that at least 86% of the variability of the resolution could be 
predicted.  
The interpretation of the optimisation results was made from the whole model 
equation rather than from the analysis of single coefficients. For that purpose, the analysis of 
the response surface plots was necessary [46, 47]. The response surfaces were obtained by 
plotting the model response against the two factors. Since econazole and miconazole 
exhibited a similar behavior, only the results obtained for one compound (miconazole) is 
presented in Figure 3A. Figure 3B illustrates the response surface of oxprenolol, which is 
comparable to that of bupivacaine, propranolol and sotalol. 
As can be seen in Figure 3A, the effect of the formic acid proportion in the mobile 
phase on enantioresolution of miconazole is fairly linear. An increase of this acidic additive 
has a negative effect on enantioresolution whereas the effect of the hexane proportion is very 
limited so that it seems possible to reach optimum enantioresolution using the lowest 
proportion of formic acid (0.015%) and no addition of n-hexane in the mobile phase.  
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From Figure 3B, it appears clearly that the formic acid proportion has a quadratic 
effect on oxprenolol enantioresolution since the response surface passes through a maximum 
near 0.2% formic acid. A similar effect is observed with bupivacaine, propranolol and sotalol. 
The n-hexane proportion seems to have no significant effect on enantioresolution for 
oxprenolol and bupivacaine but a positive effect of n-hexane addition on propranolol and 
sotalol enantioresolution is obtained using a high proportion of formic acid (0.15-0.25%). It 
results from the evalution of these response surfaces that optimum enantioresolution for these 
four chiral drugs requires a high concentration of formic acid (0.2%) and also a relatively high 
proportion of hexane in the case of propranolol and sotalol.  
These results clearly confirm that the increase of formic acid concentration up to 0.2% 
has a significant effect on the enantioseparation of the studied drugs, except for the two 
compounds with lower basic caracter (i.e. the imidazole derivatives) [25]. For most basic 
analytes, higher concentrations of the acidic additive were needed to improve 
enantioresolution.  
Optimal chromatographic conditions were generated by maximizing enantioresolution. 
The predicted resolution values and those observed experimentally were compared (Table 4). 
Very good agreement was obtained in most cases. Even if in the case of bupivacaine, 
propranolol and sotalol enantioresolution values obtained were slightly lower than those 
predicted, this is not likely to decrease significantly the quality of the model. The 
corresponding chromatograms are presented in Fig. 4. If necessary, the retention times of 
econazole and miconazole enantiomers could be reduced by a slight increase of formic acid 
concentration in the mobile phase without compromising the baseline separation since the 
enantioresolution values for these two compounds were sufficiently high. The less good S/N 
ratios observed in Fig. 4 are related to the additive percentage either lower (Fig 4. A,B) or 
higher (Fig 4. C-F) than the usual 0.1% level of formic acid in the mobile phases [25]. 
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Figure 3. Response surfaces. 
(A) Miconazole (B) Oxprenolol. 
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IV.3.3. Strategy for rapid method development 
 
Based on the optimal conditions and the effect of the factors, a set of experimental 
conditions can be proposed for rapid method development using Sepapak-4 at 25°C: ACN/ 
0.1%DEA /0.1% TFA/5% hexane. A serie of nine basic chiral compounds, namely acebutolol, 
alprenolol, atenolol, celiprolol, chlorpheniramine, isoconazole, pindolol, sulconazole and 
terbutaline were tested under these conditions and the results are presented in Table 5. As can 
be seen in this table the enantiomers of all compounds were at least partially resolved. 
Baseline enantioseparation was obtained for four compounds, namely atenolol, celiprolol, 
pindolol and terbutaline. The corresponding chromatograms are presented in Fig.5. These 
confirm the high chiral discrimination ability of Sepapak-4. An optimization step would 
probably allow to improve enantioresolution for compounds not completely enantioseparated 
under these conditions. Alternative conditions using formic acid as mobile phase additive 
were tested: ACN/0.1% DEA/0.2% FA/5% hexane. Only the enantioresolution of one 
compound, alprenolol, was improved under these conditions (1.3 instead of 0.6). It is worth 
nothing that the retention time of the second eluted peak is usually much higher with FA than 
with TFA, which seems to confirm that the nature of the acidic additive plays an important 
role in the interaction mechanisms between the analyte enantiomers and CSP as suggested 
earlier [23,25].  
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Table 4. Predicted and observed Rs values under optimal chromatographic conditions. 
Analyte 
 
Mobile phase 
 
RT (peak 2) 
(min) 
Rs 
Predicted 
(confidence 
interval at 95%) 
Observed 
Bupivacaine 
ACN/ 0.1% DEA / 0.2% FA 
15.6 3.4 [3.16-3.56] 3.1 
Oxprenolol 22.1 2.8 [2.65-2.93] 2.8 
Econazole ACN / 0.1% DEA / 0.015% 
FA 
21.7 7.8 [7.46-8.19] 7.5 
Miconazole 23.4 3.9 [3.6-4.14] 3.8 
Propranolol 
ACN / 0.1% DEA / 0.2% FA / 
9% hexane 
27.2 2.5 [2.40-2.52] 2.3 
Sotalol 
ACN / 0.1% DEA / 0.2% FA / 
7.5% hexane 
24.3 2.0 [1.93-2.07] 1.8 
Temperature: 25°C; Other conditions: see Experimental. 
Table 5. Enantioresolution values obtained using the rapid method development strategy. 
Analytes 
 
RT (peak 2)  
(min) 
Rs 
 
Acebutolol 7.4  1.0  
Atenolol 26.4  4.7  
Alprenolol 4.0  0.6 (1.3) 
Celiprolol 10.3  3.5  
Pindolol 4.3  1.9  
Isoconazole 9.2  1.0  
Sulconazole 7.1  1.1 
Terbutaline 5.9  2.2  
Chlorpheniramine 4.2  0.6  
Mobile phase: ACN / 0.1% DEA / 0.1% TFA / 5% hexane; temperature: 25°C; Other 
conditions: see Experimental.
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Figure 4 Chromatograms obtained under optimal chromatographic conditions. 
(A) Econazole; (B) Miconazole; (C) Oxprenolol; (D) Bupivacaine; (E) Propranolol;  
(F) Sotalol 
Conditions : see Experimental and Table 4. 
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Figure 5. Chromatograms obtained under the proposed strategy for rapid method 
development. 
(A) Atenolol; (B) Celiprolol; (C) Terbutaline ; (D) Pindolol 
Mobile phase: ACN/ 0.1% DEA/0.1%TFA/ 5% hexane; temperature: 25°C;  
Other conditions: see Experimental. 
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IV.4. Concluding remarks 
 
The enantioseparation of ten basic drugs were evaluated using the new commercial 
chiral stationary phase, namely Sepapak-4 in polar organic chromatography mode. These 
experiments were carried out in two steps: screening and optimisation. The results show a 
particularly strong interaction and high chiral discrimination for those basic compounds tested 
using Sepapak-4 as CSP and acetonitrile as the main mobile phase component. 
The screening step results, performed with a fractional factorial design, demonstrated 
good possibilities to regulate significantly enantioresolution by changing the type of the acidic 
additive and adding n-hexane to the mobile phase. These studies showed a large difference in 
behaviour between the compounds tested, which could be distributed in two groups according 
to the acidic additive selected: TFA or FA. Then a multivariate optimisation, using a face-
centered central composite design, has confirmed the effect of the formic acid proportion on 
enantioresolution, high resolution values being obtained for almost all compounds tested in 
relatively reasonable analysis times. 
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CHAPTER V. 
 
EVALUATION OF CHLORINE CONTAINING CELLULOSE BASED 
CHIRAL STATIONARY PHASES FOR THE LC 
ENANTIOSEPARATION OF BASIC PHARMACEUTICALS USING 
POLAR NON-AQUEOUS MOBILE PHASES 
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Summary 
 
The discrimination ability of three cellulose-based chiral stationary phases (CSPs) was 
evaluated towards the enantiomers of basic drugs, using acetonitrile as the main solvent in 
polar organic mobile phases. The study was focused on CSPs containing cellulose tris(3-
chloro-4-methylphenylcarbamate) (3-Cl-4-MePC), cellulose tris(4-chloro-3-methylphenyl-
carbamate) (4-Cl-3-MePC) or cellulose tris(3,5-dichlorophenylcarbamate) (3,5-diClPC) as 
chiral selector. The behaviour of these CSPs was studied systematically in order to investigate 
the influence of the presence and position of the chlorine substituents on the phenylcarbamate 
moieties on the retention and resolution of the enantiomers. The evaluation was made with 
three different generic mobile phases, namely ACN/0.1%DEA/0.1% TFA, ACN/0.1%DEA/ 
0.2% FA and ACN/0.1%DEA/0.2%AcA, deduced from previous work. The nature of the 
acidic additive and of the chiral selector was found to be particularly important for the 
retention and enantioresolution of these basic compounds. High resolution values could be 
obtained for most studied enantiomers with these CSPs, clearly demonstrating the interest of 
using them in combination with polar organic mobile phases. However, significant differences 
in enantioresolution between the CSPs have been observed for many compounds, indicating 
that these phases seem to be quite complementary. 
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V.1. Introduction 
 
Polysaccharide derivatives belong to the most commonly used chiral stationary phases 
(CSPs) for the direct liquid chromatographic (LC) enantioseparation of chiral compounds. 
Indeed, more than 90% of the determinations of enantiomeric excess by chiral LC method are 
performed using the polysaccharide-based CSPs [1,2]. Among these CSPs, those with 
cellulose or amylose phenylcarbamate derivatives as chiral selectors, have a wide application 
range [3-8]. The chiral recognition abilities of the cellulose phenylcarbamate derivatives can 
be controlled by the nature of the substituents on the phenyl groups [2]. Moreover, the 
cellulose phenylcarbamates with electron-withdrawing substituents such halogens, or 
electron-donating substituents, such as alkyl groups, exhibit higher chiral recognition than the 
non-substituted one [2, 5]. These substituents seem to influence the polarity of the carbamate 
group through an inductive effect and change the interaction mode between the cellulose 
derivatives and the chiral compound. On the other hand, the chiral recognition on the 
phenylcarbamate derivatives is also influenced by the position of the substituents on the 
phenyl group of the polymer [9, 10]. Based on these facts, many possibilities for cellulose 
phenylcarbamate derivatives chiral selectors can be proposed. Chankvetadze et al. have 
developed since a decade two cellulose derivatives having both electron-withdrawing 
(chlorine atom) and electron-donating (methyl group) substituents in positions 3 and/or 4 of 
the phenyl moiety of the polymer, namely cellulose tris(3-chloro-4-methylphenylcarbamate) 
(3-Cl-4-MePC) and cellulose tris(4-chloro-3-methylphenylcarbamate) (4-Cl-3-MePC), as well 
as a cellulose derivative with two electron-withdrawing substituents (chlorine atoms) in 
position 3 and 5 on the phenyl group of the polymer namely cellulose tris(3,5-
dichlorophenylcarbamate) (3,5-diClPC) [11-15]. 
Since the commercialization of these polysaccharide-based CSPs, little emphasis has 
been made on the study of the effects of factors, such as the nature and concentration of acidic 
additives. These factors were found to play a crucial role in polar organic chromatography 
with respect to retention and enantioresolution using 4-Cl-3-MePC [16,17]. As far as we 
know, although some previous studies have mentioned their recognition abilities in NPLC [6, 
13, 18] and polar organic solvent chromatography (POSC) [19-21], no systematic 
comparative study has been reported in POSC about the use of these three chlorine containing 
cellulose-based CSPs with different acidic additives for chiral resolution. 
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In the present study, the chiral recognition ability of these three CSPs, namely 3-Cl-4-
MePC, 4-Cl-3-MePC and 3,5-diClPC, was evaluated towards the enantiomers of thirteen 
basic drugs  using acetonitrile as main solvent with basic and acidic additives in POSC. The 
purpose of this evaluation is to compare enantioseparation abilities of these CSPs under three 
rapid screening conditions, ACN/0.1%DEA/0.1% TFA and ACN/0.1%DEA/ 0.2% FA, 
ACN/0.1%DEA/0.2%AcA deduced from our previous work [16,17].  
 
 
V.2. Experimental 
V.2.1. Chemicals and reagents 
 
Acebutolol hydrochloride, metoprolol tartrate, oxprenolol hydrochloride, propranolol 
hydrochloride, econazole nitrate and prilocaine hydrochloride were supplied by Sigma–
Aldrich (Saint-Louis, MO, USA). Celiprolol hydrochloride was provided by Rorer (Brussels, 
Belgium), miconazole nitrate by Janssen Pharmaceutica (Beerse, Belgium), sotalol 
hydrochloride by Profarmaco Combrex (Milan, Italy), atenolol by Erregierre (Bergamo, 
Italy), betaxolol by LERS (Paris, France), bupivacaine hydrochloride by Astra Pharmaceutical 
Products (Södertalje, Sweden) and mepivacaine hydrochloride by Federa (Brussels, Belgium). 
All samples are racemates used without further purification. 
Acetonitrile (ACN) of HPLC grade and glacial acetic acid (AcA) pro analysi were 
provided by Merck (Darmstadt, Germany). Trifluoroacetic acid (TFA), diethylamine (DEA) 
and formic acid (FA) pro analysi were obtained from Acros Organics (Geel, Belgium). 
 
 
V.2.2. Instrumentation 
 
The chromatographic system from Agilent Technologies (Waldbronn, Germany) 
consisted in a binary pump, a thermostated column compartment, a diode array detector and 
an automatic injector, all of 1100 series. The Chemstation software was used for system 
control and data acquisition. Three chiral columns (250 x 4.6 mm; i.d.), namely Sepapak-2
®
 
(3-Cl-4-MePC), Sepapak-4
®
 (4-Cl-3-MePC) and Sepapak-5
®
 (3,5-diClPC), were kindly 
supplied by Sepaserve (Münster, Germany). The chiral selectors coated on 
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aminopropylsilanized silica (nominal particle size 5µm) were cellulose tris (3-chloro-4-
methylphenylcarbamate), cellulose tris (4-chloro-3-methylphenylcarbamate) and cellulose tris 
(3,5-dichlorophenylcarbamate) for 3-Cl-4-MePC, 4-Cl-3-MePC and 3,5-diClPC respectively, 
in the amount of 25% (w/w). Figure 1 presents the chemical structure of these chiral selectors. 
 
 
 
 
3-chloro-4-methylphenylcarbamate (A)       4-chloro-3-methylphenylcarbamate (B)  
 
 
 
 
 
Cellulose modified polymers 
 
 
 
3,5-dichlorophenylcarbamate (C) 
 
Figure 1. Structure of cellulose derivated chiral selectors of the studied CSPs 
3-Cl-4-MePC (A); 4-Cl-3-MePC (B); 3,5-diClPC (C). 
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V.2.3. Solutions for method development 
 
Solutions of each racemic compound at a concentration of ca 100 µg/ml were prepared 
by dissolving the appropriate amount of the substance in the required volume of mobile 
phase. 
 
 
V.2.4. Chromatographic conditions 
 
The mobile phases consisted of a mixture of acetonitrile, acidic additive (TFA, FA or 
AcA) and diethylamine (DEA) (v/v) and were pumped at a constant flow-rate of 1.0 mL/min. 
A low concentration of DEA, i.e. 0.1%, was added to the mobile phase in order to obtain 
efficient and symmetrical peaks. The injection volume was 20 µL. The analytes were detected 
photometrically at 220 nm and the temperature was settled at 25°C in all experiments. 
 
 
V.3. Results and discussion 
 
In previous work, the influence of the acidic additive (TFA, AcA or FA) on the 
enantioresolution and retention of chiral basic pharmaceuticals was demonstrated in LC using 
ACN and a CSP with cellulose tris(4-chloro-3-methylphenylcarbamate) as chiral selector (4-
Cl-3-MePC)) [16,17]. The strategy proposed for rapid screening method development only 
included TFA (at 0.1%) and FA (at 0.2%) but it is worth noting that AcA was also shown to 
significantly influence the enantioresolution of some chiral compounds [17]. Therefore, the 
three acidic additives were included in the present study devoted to the comparison of the 
behaviour of three chlorine containing cellulose-based CSPs, namely 3-Cl-4-MePC, 4-Cl-3-
MePC and 3,5-diClPC. 
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V.3.1. Effect of the nature of the acidic additive and the chiral selector 
 on retention 
 
Tables 1, 2 and 3 present the retention factors (k‟1) of the first eluting enantiomers on 
the studied CSPs using the three different acidic additives as well as enantioselectivity and 
enantioresolution values. Using TFA (cf. Table 1),  most chiral compounds have low retention 
factors (k‟1< 2), irrespective of the nature of the CSP. It can therefore be assumed that the 
mobile phase containing TFA (i.e. ACN/0.1%DEA/0.1% TFA) has a very high elution 
strength. In the presence of this acid in the mobile phase, retention factors obtained on 3,5-
diClPC were especially low compared to those observed on 3-Cl-4-MePC and 4-Cl-3-MePC. 
With AcA as acidic additive instead of TFA (cf. Table 2), a general tendency to an increase in 
retention can be observed. The retention of most compounds was again the lowest on 3,5-
diClPC. However, the three local anesthetics were found to have higher retention on 3,5-
diClPC using AcA. 
Irrespective of the nature of the CSP, FA led to the highest retention in most cases (cf. 
Table 3). With this acidic additive, the retention of most compounds was also the lowest on 
3,5-diClPC. The higher retention generally observed using 3-Cl-4-MePC and 4-Cl-3-MePC 
could be explained by the presence of one methyl substituent on the phenylcarbamate groups 
of these CSPs. Indeed, electron-donating substituents like methyl groups increase the electron 
density at the carbonyl of the carbamate group and thus the retention time, since hydrogen-
bonding interaction between the chiral analyte and the CSP can be promoted [2]. It is 
noteworthy that econazole and miconazole have an opposite retention behavior, their retention 
being higher on 3,5-diClPC than on the two other CSPs in the presence of FA in the mobile 
phase. Sotalol has also a peculiar retention behavior with the same acidic additive since its 
retention was much lower on 4-Cl-3-MePC (k‟1: 1.2) than on 3-Cl-4-MePC (k‟1: 8.7) and 
3,5-diClPC (k‟1: 3.8). These results suggest that in the presence of a weaker acid such as AcA 
or FA, the retention mechanisms become more complex and analyte-dependent. 
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V.3.2. Effect of the nature of the acidic additive and the chiral selector 
on enantioseparation 
 
Tables 1, 2 and 3 also illustrate the influence of the nature of the acidic additive and 
the CSP on the enantioselectivity and enantioresolution of the studied basic drugs. As can be 
seen in Table 1, TFA seems to be particularly useful for the enantioseparation of the studied 
compounds with 4-Cl-3-MePC as CSP compared to 3-Cl-4-MePC. On the contrary, complete 
enantioseparation could not be obtained for the studied compounds on 3,5-diClPC. This 
suggests that the use of this acidic additive should be avoided for enantioseparation on 3,5-
diClPC, probably related to the very low retention under these conditions (cf. Section 3.1). 
Even if several compounds such as prilocaine can be fully resolved with 3-Cl-4-MePC, the 
highest enantioresolution values were obtained with 4-Cl-3-MePC (cf. Fig. 2A). 
 
 
Figure 2. Influence of the nature of the chiral selector on enantioresolution of prilocaine (A) 
and acebutolol (B). 
Mobile phase: ACN/0.1% DEA/0.1% TFA (A) or 0.2% AcA (B).  
Other conditions: see Section 2. 
 
(A) (B) 
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With AcA as acidic additive, a completely different behavior was observed: the 
majority of the compounds show higher enantioresolution values using 3,5-diClPC compared 
to 4-Cl-3-MePC (cf. Table 2). For example, complete enantioseparation for acebutolol was 
only obtained on 3,5-diClPC using AcA (cf. Fig. 2B). In this particular case, a partial 
resolution occurs on 3-Cl-4-MePC while no resolution was observed on 4-Cl-3-MePC. 
As can be seen from Table 3, the use of FA as acidic additive for the enantioseparation 
of beta-blockers gives rise to the highest discrimination ability on 3,5-diClPC  On the 
contrary, for most of the other drug enantiomers, the highest resolution values were obtained 
on 4-Cl-3-MePC with FA as additive. 
As shown in Figure 3, the resolution of sotalol and miconazole enantiomers was 
higher in the presence of AcA compared to FA using 3,5-diClPC as CSP while no 
enantioseparation is observed with TFA. Furthermore, for the enantiomers of some drugs like 
the imidazole derivatives, the use of either FA or AcA was found to be suitable for complete 
enantioseparation irrespective of the nature of the CSP (cf. Tables 2 and 3). 
 
 
 
 
 
 
 
 
Figure 3. Effect of the nature of the acidic additive on enantioresolution of sotalol and 
miconazole enantiomers using 3,5-diClPC as CSP. 
Mobile phase: ACN/0.1% DEA/0.1%TFA or ACN/0.1% DEA/0.2% (FA or AcA);  
Peaks: (1 and 1‟)- enantiomers of miconazole; (2 and 2‟)- enantiomers of sotalol.  
Other conditions: see Section 2. 
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Table 1. Influence of the chiral selector nature on the retention factor (k’1), the 
enantioselectivity (α) and enantioresolution (Rs) of the studied basic amino-drugs enantiomers 
using TFA as acidic additive. 
 
3-Cl-4-MePC 4-Cl-3-MePC 3,5-diClPC 
k’1 α Rs k’1 α Rs k’1 α Rs 
Acebutolol 1.90 1.08 0.7 1.50 1.10 1.1 0.64 1.07 1.0 
Atenolol 5.0 1.44 4.8 5.1 1.41 5.3 1.28 1.15 1.2 
Betaxolol 0.77 1.22 1.4 0.55 1.26 2.1 0.18 1.03 0.7 
Celiprolol 2.8 1.27 2.6 2.2 1.36 3.5 1.29 1.09 1.2 
Metoprolol 0.71 1.16 0.9 0.48 1.06 0.6 0.16 1.03 0.7 
Oxprenolol 0.66 - - 0.38 1.12 0.9 0.12 1.03 0.7 
Propranolol 0.52 - - 0.28 - - 0.14 - - 
Sotalol 0.50 - - 0.16 - - 0.07 - - 
Econazole 1.60 1.14 1.4 1.31 1.16 1.7 0.63 1.03 0.6 
Miconazole 2.3 1.08 0.9 1.90 1.12 1.5 0.91 - - 
Bupivacaine 1.20 1.08 0.6 0.72 - - 0.38 1.02 0.6 
Mepivacaine 0.41 1.28 1.3 0.64 1.13 1.2 0.37 - - 
Prilocaine 0.77 1.56 3.9 0.55 2.47 8.5 0.21 - - 
 „–‟ no enantioresolution observed. Mobile phase: ACN/0.1% DEA/0.1% TFA;.  
Other conditions: see Section 2.  
  Chapter V. 
99 
Table 2. Influence of the chiral selector nature on the retention factor (k’1), the 
enantioselectivity (α) and enantioresolution (Rs) of the studied basic amino-drugs enantiomers 
using AcA as acidic additive. 
 
3-Cl-4-MePC 4-Cl-3-MePC 3,5-diClPC 
k’1 α Rs k’1’ α Rs k’1 α Rs 
Acebutolol 10.9 1.09 0.9 11.9 - - 6.9 1.34 3.4 
Atenolol / / / / / / / / / 
Betaxolol 4.9 1.16 1.8 5.4 1.09 1.3 3.3 1.34 3.6 
Celiprolol 15.2 1.15 1.6 15.08 1.15 2.3 12.6 1.32 3.5 
Metoprolol 4.8 1.13 1.6 5.0 1.06 0.8 3.1 1.38 4.0 
Oxprenolol 3.8 1.18 2.1 3.7 1.14 2.0 1.29 1.46 4.3 
Propranolol 4.0 1.07 0.9 4.6 1.12 1.8 2.12 1.18 2.1 
Sotalol 4.3 1.26 3.0 4.1 1.15 1.9 3.8 1.15 1.4 
Econazole 2.4 1.41 4.4 2.6 1.52 4.7 2.8 1.23 2.7 
Miconazole 3.5 1.25 3.1 3.5 1.28 3.9 4.3 1.20 2.7 
Bupivacaine 0.9 1.03 0.6 0.62 - - 1.11 1.08 0.6 
Mepivacaine 0.69 1.17 1.3 0.65 1.13 1.3 1.09 1.28 2.5 
Prilocaine 0.45 1.27 1.5 0.29 1.30 2.1 0.49 - - 
 „/‟ no peak obtained within 60 min. „–‟ no enantioresolution observed. Mobile phase: 
ACN/0.1% DEA/0.2% AcA. Other conditions: see Section 2.  
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Table 3. Influence of the chiral selector nature on the retention factor (k’1), the 
enantioselectivity (α) and enantioresolution (Rs) of the studied basic amino-drugs enantiomers 
using FA as acidic additive 
 
3-Cl-4-MePC 4-Cl-3-MePC 3,5-diClPC 
k’1 α Rs k’1 α Rs k’1 α Rs 
Acebutolol 10.9 1.06 0.7 12.7 1.1 1.5 5.1 1.32 4.0 
Atenolol / / / / / / 11.6 1.37 5.3 
Betaxolol 4.4 1.12 1.6 6.8 1.06 0.8 2.1 1.19 2.4 
Celiprolol 16.2 1.11 1.3 / / / 8.4 1.20 2.7 
Metoprolol 8.5 1.10 1.4 12.4 - - 5.1 1.04 2.8 
Oxprenolol 6.7 1.17 2.0 9.6 1.16 2.5 3.2 1.19 2.4 
Propranolol 9.8 1.08 1.0 12.2 1.15 2.4 5.2 1.06 0.7 
Sotalol 8.7 1.06 0.7 1.2 1.14 1.8 3.8 1.06 0.7 
Econazole 3.9 1.29 3.4 4.1 1.33 4.7 4.3 1.2 2.0 
Miconazole 5.8 1.15 1.9 5.7 1.13 2.0 6.7 1.17 2.2 
Bupivacaine 2.4 1.17 2.0 2.8 1.21 3.0 1.69 1.11 1.2 
Mepivacaine 1.93 1.19 2.0 2.6 1.2 2.8 1.80 1.23 0.5 
Prilocaine 1.69 - - 1.9 - - 1.08 - - 
 „/‟ no peak obtained within 60 min. „–‟ no enantioresolution observed. Mobile phase: 
ACN/0.1% DEA/0.2% FA. Other conditions: see Section 2.  
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Table 4 gives the acidic additive leading to the highest Rs value obtained with each 
CSP. As can be seen in this Table, it appears that all tested compounds could be completely 
enantioseparated in most cases. Only for enantiomers of prilocaine, no enantioresolution was 
observed using 3,5-diClPC. 4-Cl-3-MePC seems to have a particularly high resolving power 
since twelve basic chiral drugs of the thirteen tested were completely resolved and in most 
cases the Rs values were higher with either FA or TFA, except sotalol and miconazole for 
which AcA led to the highest enantioresolution. Enantioresolution values were higher with 
either FA or AcA using 3,5-diClPC, as already observed in Fig.3. In the case of 3-Cl-4-
MePC, the three acidic additives seem to be necessary for the enantioseparation of the model 
compounds.  
Moreover, the Rs values observed were generally the lowest on 3-Cl-4-MePC except 
for sotalol. Therefore, using the appropriate acidic additive, it was possible to resolve the 
enantiomers of all the basic drugs tested (maximum Rs value: 2.4-8.5), which demonstrates 
the high resolving power of these CSPs. 
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Table 4. Conditions for maximum enantioresolution for differents CSPs used 
 
3-Cl-4-MePC 4-Cl-3-MePC 3.5-diClPC 
Rs max 
Acidic  
additive 
Rs max 
Acidic 
additive  
Rs max 
Acidic 
additive 
Acebutolol 0.9 AcA 1.5 FA 4.0 FA 
Atenolol 4.8 TFA 5.3 TFA 5.3 FA 
Betaxolol 1.8 AcA 2.1 TFA 3.6 AcA 
Celiprolol 2.6 TFA 3.5 TFA 3.5 AcA 
Metoprolol 1.6 AcA 1.2 TFA 4.0 AcA 
Oxprenolol 2.1 AcA 2.5 FA 4.3 AcA 
Propranolol 1.0 FA 2.4 FA 2.1 AcA 
Sotalol 3.0 AcA 1.9 AcA 1.4 AcA 
Econazole 4.4 AcA 4.7 FA 2.7 AcA 
Miconazole 3.1 AcA 3.9 AcA 2.7 AcA 
Bupivacaine 2.0 FA 3.0 FA 1.2 FA 
Mepivacaine 2.0 FA 2.8 FA 2.5 AcA 
Prilocaine 3.9 TFA 8.5 TFA - - 
 „–‟ no enantioresolution observed. Mobile phase: ACN/0.1% DEA/0.1% (TFA) or  
0.2% (AcA or FA); Other conditions: see Section 2. 
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V.4. Concluding remarks 
 
The three chlorine containing cellulose based CSPs tested in polar organic solvent 
chromatography with different acidic additives, namely TFA, AcA or FA in the mobile phase, 
have showed quite different enantioseparation capabilities. 3-Cl-4-MePC was found to have 
an intermediate behavior leading to lower enantioresolution values compared to 4-Cl-3-MePC 
and 3,5-diClPC. The two latter CSPs seem to be complementary so that the screening strategy 
can be limited to the combination of 4-Cl-3-MePC with TFA or FA and 3,5-diClPC with FA 
or AcA. Under these conditions involving at most four experiments, it was possible to 
enantioresolve each of the thirteen studied compounds. However, 4-Cl-3-MePC can be 
considered as the most useful of these three CSPs using ACN as main solvent.  
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  CHAPTER VI 
 
DEVELOPMENT AND VALIDATION OF A LC METHOD FOR THE 
ENANTIOMERIC PURITY DETERMINATION OF S-ROPIVACAINE 
IN A PHARMACEUTICAL FORMULATION USING A CHLORINE 
CONTAINING CELLULOSE-BASED CHIRAL STATIONARY PHASE 
AND POLAR NON-AQUEOUS MOBILE PHASE 
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Summary 
 
Ropivacaine is the first enantiomerically pure long-acting local anaesthestic used for 
surgical anaesthesia and post-operative pain relief.  
A liquid chromatographic (LC) method using acetonitrile as the main solvent and 
cellulose tris(4-chloro-3-methylphenylcarbamate) coated on silica as chiral stationary phase 
was successfully developed and applied for the enantiomeric purity determination of S-
ropivacaine in a pharmaceutical formulation (Naropin®). The key role played by the acidic 
additive (trifluoroacetic acid or formic acid) in the enantioseparation of basic drugs in these 
LC systems was demonstrated by the reversal of ropivacaine enantiomers elution order 
observed when both acids were compared. In order to elute the enantiomeric impurity (R-
ropivacaine) before S-ropivacaine, formic acid (FA) was selected. The temperature and the 
percentages of acidic additive and hexane in the mobile phase were found to significantly 
influence the retention and resolution of these enantiomers. The optimized mobile phase 
consisted of ACN/0.1% DEA/0.2% FA/5% hexane (v/v/v/v). The temperature was set at 35°C 
to avoid the interference from a peak system related to the presence of water in the sample on 
ropivacaine enantiomers.  
The LC method was then fully validated applying the strategy based on total 
measurement error and accuracy profiles. The accuracy profile obtained by linear regression 
after square root transformation was selected, the acceptance limits being settled at ±10% for 
the intended use of this analytical method. The relative bias was lower than 1.5%, while the 
RSD values for repeatability and intermediate precision were both below 1.0%. The limit of 
detection (LOD) and the lower limit of quantification (LLOQ) were found to be about 0.2 and 
1.0 µg/mL, respectively, corresponding to 0.02 and 0.1% of the enantiomeric impurity in S-
ropivacaine.  
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VI.1. Introduction 
 
Chirality has become a very important topic in pharmacology and analytical chemistry 
since a thorough assessment of potential chiral drug candidates is required in drug 
development by the Food and Drug Administration (FDA) and the European Medicines 
Evaluation Agency (EMEA) [1,2]. These guidelines recommend to test the new chiral drug 
molecules in their racemic form as well as single-isomers in the various stages of 
development. Both regulatory bodies recommend the use of validated methods to evaluate the 
enantiomeric purity of single-isomers. 
Ropivacaine is the first enantiomerically pure local anesthetic available for therapeutic 
use. It belongs to the same structural group (pipecoloxylidide) as bupivacaine and 
mepivacaine used for many decades as racemates. Even though (R)- and (S)-(-)-1-propyl-
2‟,6‟-pipecoloxylidide have similar nerve blocking properties, S-ropivacaine has shown less 
cardiotoxicity than the R-enantiomer as it is also the case for bupivacaine [3, 4, 5]. 
Ropivacaine has then been developed as a pure enantiomer and is currently used in epidural 
anesthesia and post operative pain [6].  
Sänger-van de Griend et al. have developed a capillary electrophoretic method for the 
enantiomeric purity determination of ropivacaine using heptakis (2,6-di-O-methyl)-β-
cyclodextrin as chiral selector [7, 8]. The method was found to be specific, linear, robust, 
accurate with a LOQ of 0.1% for the enantiomeric impurity. Nevertheless, the analysis time 
(about 25 min) as well as the LOD (0.05%) could be improved. 
In a pending monograph of ropivacaine from the United States Pharmacopeia (USP), 
the enantiomeric purity of ropivacaine is determined by a LC method [9]. The separation was 
achieved on a chiral-AGP column (150 mm x 4.0 mm i.d., 5 µm). The mobile phase consisted 
of isopropyl alcohol and monobasic sodium phosphate buffer (1:9, v/v). Under the prescribed 
experimental conditions, the run time was about 15 minutes and an enantioresolution of 1.8 
between S-ropivacaine and its enantiomeric impurity was obtained. Eriksson Möller reported 
a very similar LC method for which a detection limit of 0.1% for the enantiomeric impurity 
was observed [10]. 
The main goal of the present work was to develop and validate a selective, precise, 
accurate and reliable LC method for the determination of R-ropivacaine in S-ropivacaine 
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pharmaceutical formulation (Naropin®, 10 mg/mL solution). The method should be suitable 
for routine quality control of S-ropivacaine and the run time should be less than 15 min. To 
achieve this purpose, the newly commercialized chiral stationary phase (CSP), namely 
cellulose tris(4-chloro-3-methylphenylcarbamate) coated on silica (Sepapak-4), which showed 
a good enantioresolution for local anesthetics like bupivacaine and mepivacaine, was used 
[11, 12]. Moreover, the developed method was fully validated according to the strategy 
proposed by a Commission of the Société Française des Sciences et Techniques 
Pharmaceutiques [13]. This strategy is based on the use of accuracy profiles which take into 
account the total error, i.e. estimation of systematic and random errors of measurement 
results. 
 
 
VI.2. Experimental 
VI.2.1. Chemicals and reagents 
 
Ropivacaine hydrochloride monohydrate and ropivacaine impurity G were supplied by 
EDQM (Strasbourg, France). Ropivacaine chemical structure is presented in fig.1. Naropin® 
(10mg/mL) was supplied by NV Astra Zeneca SA (Brussel, Belgium). Acetonitrile (ACN) of 
HPLC grade and glacial acetic acid (AcA) pro analysis were provided by Merck (Darmstadt, 
Germany). Trifluoroacetic acid (TFA), diethylamine (DEA), and formic acid (FA) pro 
analysis were obtained from Acros Organics (Geel, Belgium). n-Hexane of HPLC grade was 
from BDH Hypersol (Poole, UK). 
 
 
 
 
 
Figure 1. Chemical structure of ropivacaine. 
CH3
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 VI.2.2. Instrumentation 
 
The chromatographic system from Agilent Technologies (Waldbronn, Germany) 
consisted in a binary pump, a thermostated column compartment, a diode array detector and 
an automatic injector, all of 1200 series. The Chemstation software was used for system 
control and data acquisition. The chiral column Sepapak-4 (250 mm x 4.6 mm I.D.) was 
kindly provided by Sepaserve (Münster, Germany). The chiral selector adsorbed on 
aminopropylsilanized silica was cellulose tris(4-chloro-3-methylphenylcarbamate).  
The statistical calculations for validation were performed by means of e.noval version 
3.0 software (Arlenda, Liège, Belgium). 
 
 
VI.2.3. Standards solutions  
VI.2.3.1. Sample solutions used for method development  
 
Different stock solutions of R- and S-ropivacaine were prepared by dissolving an 
accurately weighed amount of approximately 1 mg of each compound in 10 ml of ACN. The 
stock racemate solution was prepared by dissolving a weighed amount of approximately 1 mg 
for R ropivacaine and 1.1 mg for S-ropivacaine in 10 mL of ACN. This stock solution was 
then diluted 5-fold to obtained a final solution of 20 µg/mL. 
 
VI.2.3.2. Sample solutions used for validation 
 
 A stock solution of R-ropivacaine was prepared by dissolving an accurately weighed 
amount of approximately 5 mg of this compound in 100 mL of the LC mobile phase. Then 
subsequent dilutions were achieved in order to obtain five calibration standards ranging from 
1.0 to 15 µg/mL (m=5) (cf. Table 1). Two replicates (n=2) were prepared per concentration 
level. Each solution is injected one time. The number of concentration levels was sufficient to 
generate different regression models. 
A stock solution of S-ropivacaine was prepared by diluting ten-fold the aqueous 
solution of Naropin (10 mg/mL) in the LC mobile phase. The final concentration of S-
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ropivacaine was 1 mg/mL. Then three independent series of validation standards were 
prepared by spiking the correct volume of the R-ropivacaine stock solution in a sufficient 
volume of S-ropivacaine stock solution in order to reach final concentrations of 1, 2, 5 and 15 
µg/mL (m=4) of the enantiomeric impurity (cf. Table 1). Three replicates (n=3) were prepared 
per concentration level and each one was injected one time. 
 
 
VI.2.4. Chromatographic conditions 
 
The mobile phases consisted in a mixture of acetonitrile, organic modifier (hexane), 
acidic additive and basic additive (v/v) and were pumped at a constant flow-rate of 1.0 
mL.min-1. In all experiments, the basic additive percentage in the mobile phase was settled at 
0.1 %. The optimal mobile phases was made up of ACN/0.1% DEA/0.2% FA/ 5% hexane. 
The injection volume was 10 µL. The analytes were detected photometrically at 240 nm.  
 
Table 1. Preparation of standard solutions related to R-ropivacaine for validation. 
Concentration  level (% relative to  
1.0 mg/mL of S-ropivacaine) 
Concentration of R-ropivacaine (µg/mL) 
Calibration standards Validation standards 
0.1 1.0 1.0 
0.2 2.0 2.0 
0.5 5.0 5.0 
1.0 10.0 - 
1.5 15.0 15.0 
total 10 samples/day 12 samples/day 
 
 
 
  Chapter VI. 
111 
VI.3. Results and discussion 
VI.3.1. Method development 
 
In a previous work, an experimental design was applied for the enantioresolution of 
ten basic drugs, including bupivacaine and mepivacaine [12]. The optimal mobile phases 
consisted of ACN/0.1% DEA/0.1% FA/ 5% hexane for mepivacaine and ACN/0.1% 
DEA/0.2% FA for bupivacaine. For both methods, the temperature was set at 25°C. 
Moreover, this study highlighted the fact that the enantiomeric resolution of chiral 
pharmaceuticals on Sepapak-4 was influenced by the nature and the percentage of the acidic 
additive and hexane in the mobile phase [11, 12]. Finally, a strategy for rapid method 
development using a mobile phase made up of 0.2% FA, 5% hexane with ACN and 0.1% 
DEA at 25°C was proposed. Therefore, these experimental conditions were applied for the 
enantiomeric resolution of ropivacaine. As can be seen in Fig.2, under these conditions, 
ropivacaine enantiomers were completely resolved (Rs value: 3.0) in a relatively short 
analysis time (14 min).  
 
 
Figure 2. Influence of the nature and the percentage of the acidic additive on the retention 
time of the second peak and on enantioresolution. 
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 In order to verify that the generic conditions were the best for ropivacaine enantiomers 
with respect to retention time and enantioresolution, experiments were performed using other 
acidic additives (TFA and AcA), different FA and n-hexane percentages (cf. Figs. 2A and B). 
As expected, the nature of the acidic additive has a strong influence on the enantioresolution 
of ropivacaine. Indeed, only FA (at a percentage of at least 0.1%) leads to a complete 
separation of ropivacaine enantiomers. An increase of FA concentration up to 0.2% has a 
positive effect on the enantioresolution and retention of the enantiomers. Moreover, the 
presence of 5% - 10% of n-hexane in the mobile phase gives rise to a small decrease of the 
analysis time and also slightly improves enantioresolution.  
It is noteworthy that the elution order of ropivacaine enantiomers depends on the 
nature of the acidic additive. Indeed, as can be seen in Figs. 3A and B, when TFA was used as 
acidic additive, S-ropivacaine was the first eluting peak whereas an opposite elution order was 
observed with FA under these conditions. Therefore, FA was kept as acidic additive since the 
impurity eluted before the main compound. Indeed, to avoid possible interference in the 
enantiomeric purity determination caused by the tailing of the main enantiomer present in 
high concentration, the elution order is of utmost importance, especially when the 
enantioseparation is minimal [14, 15]. Here, it is clearly an advantage of these LC systems to 
enable a reversal of the elution order by changing the nature of the acidic additive. 
As can be seen in Figs. 3C and D, the same elution order was observed using Sepapak-
2 (chiral selector: cellulose tris(3-chloro-4-methylphenylcarbamate)) with similar changes in 
the mobile phase. Interestingly, this reversal of elution order only occurred using these two 
CSPs which have both electron-withdrawing (chlorine) and electron-donating (methyl) groups 
on the phenylcarbamate moiety. Indeed, no reversal of ropivacaine enantiomers elution order 
was observed using Chiralcel ODH or Sepapak-5 with either two electron-donating or two 
electron-withdrawing groups in positions 3 and 5 of the phenylcarbamate moiety (data not 
shown). Therefore, the key role of the acidic additive in the reversal of ropivacaine 
enantiomers elution order could be related to the simultaneous presence of methyl and 
chlorine groups on the phenylcarbamate moiety of Sepapak-2 and -4. 
Finally, taking into account the desired elution order, a short analysis time without 
jeopardizing enantioresolution, a mobile phase made up of ACN/0.1% DEA/0.2% FA/5% 
hexane was selected for this application. Fig. 4A illustrates the chromatogram of ropivacaine 
enantiomers using this mobile phase at 25°C. 
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Nevertheless, when analyzing a validation sample, a peak system related to the 
presence of water in the sample appeared between ropivacaine enantiomers, which disturbed 
the quantification of the targeted impurity. To overcome this problem, the temperature was set 
at 35°C and, as can be seen in Figs. 4B and C, the peak system was then located after S-
ropivacaine peak and therefore did no longer interfere in the determination of the 
enantiomeric impurity. However, as already observed earlier, this change of temperature had 
no significant effect on enantioresolution [11, 12]. 
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Figure 3. Chromatograms showing the reversal of  ropivacaine enantiomers elution order 
according to the nature of the acidic additive. 
Mobile phase: ACN/0.1% DEA/0.1% FA (A, C), ACN/0.1% DEA/0.1% TFA (B,D); Flow 
rate: 1 mL/min; Temperature: 25°C; UV detection: 240 nm; CSP: Sepapak-4 (A,B), 
 Sepapak-2 (C,D). 
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Figure 4. Typical chromatograms of a) a solution of racemic ropivacaine (20 µg/mL); b) 
water diluted in the mobile phase; c) a solution of S-ropivacaine (1 mg/mL of diluted 
Naropin®) containing R-ropivacaine (1 µg/mL); d) a solution of S-ropivacaine (1 mg/mL of 
diluted Naropin®). 
Mobile phase: ACN/0.1% DEA/0.2% FA/5% Hexane, Flow-rate: 1 mL/min; Temperature: 
25°C (A) and 35°C (B,C,D), UV: 240 nm; CSP: Sepapak-4. Other conditions see Section 2. 
 
(C) (D) 
(B) (A) 
  Chapter VI. 
116 
VI.3.2. Method validation 
 
The validation approach, based on total measurement error and accuracy profiles as 
decision tool, was applied to demonstrate that the developed method is suited for its intended 
purpose [13, 16, 17]. This strategy was elaborated by a SFSTP (Société Française des 
Sciences et Techniques Pharmaceutiques) Commission. The concept of accuracy profile was 
also used to select the most appropriate calibration model, to determine the lower limit of 
quantification and the range over which the method can be considered as valid. 
 
VI.3.2.1. Selectivity 
 
To evaluate method selectivity, the chromatograms obtained by analyzing water 
diluted in the mobile phase and a sample of S- and R-ropivacaine, were compared in order to 
check the absence of compounds likely to interfere in the quantification of R-ropivacaine. As 
can be seen in Figs. 4A and B, no interference was observed at the retention time of the peak 
corresponding to R-ropivacaine. It is worth noting that even though the peak corresponding of 
water interferes slightly with S-ropivacaine peak, it does not compromise the quantification of 
the enantiomeric impurity.  
Moreover, a solution of S-ropivacaine (1 mg/mL), obtained by diluting ten-fold 
Naropin®, was analysed (cf. Fig. 4D). As can be seen from this figure, a small peak, 
identified as R-ropivacaine by comparison of the retention times, was observed. Therefore, 
three independent injections of this solution was carried out daily and, at each validation day, 
the mean peak area of R-ropivacaine was subtracted from the responses of the validation 
standards.  
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Figure 5. Accuracy profiles obtained using a) a linear regression model. b) a weighted linear 
regression model with a weight equal to 1/X. c) a weighted linear regression model with a 
weight equal to 1/X
2
. d) a linear regression model after square root transformation. e) a linear 
regression model after logarithm transformation. f) a quadratic regression model. The plain 
line is the relative error (%), the dashed lines correspond to the accuracy profile i.e. to the β-
expectation tolerance limits expressed in relative error, and the dotted curves represent the 
acceptance limits (±10%). 
(A) (B) 
(C) (D) 
(E) (F) 
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VI.3.2.2. Selection of the calibration model 
 
Several regression models were fitted to the calibration standards. From each 
regression line obtained, the concentrations of the validation standards were back-calculated 
in order to determine, at each concentration level, the mean relative bias, the relative standard 
deviation for intermediate precision as well as the upper and lower β-expectation tolerance 
limits at 95% [13]. 
Taking into account the validation data, several accuracy profiles were plotted to 
select the most suitable regression model for the intended use of the analytical method, as 
illustrated in Fig. 5. Six response functions, namely the simple linear regression, the weighted 
(1/X) and (1/X
2
) linear regression models, the linear regression models after square root and 
logarithm transformation as well as the quadratic regression model, were tested. The 
acceptance limits were set at ±10% according to the regulatory requirements [18-20].  
All these response functions allowed to demonstrate the capability of the method over 
the concentration range considered, since the tolerance intervals were totally included inside 
the acceptance limits as shown in Fig. 5. However, the linear regression model after square 
root transformation seems to be the best. Indeed, the relative error is the lowest especially at 
the two first concentration levels. The variability of the results is also weak. Table 2 presents 
the validation results obtained by applying this linear regression model.  
 
VI.3.2.3.Trueness 
 
Trueness refers to the closeness of agreement between a conventionally accepted value 
or reference value and a mean experimental one. It gives information on systematic error and 
is expressed in term of relative bias (%). As can be seen in Table 2, the relatives biases 
assessed from the validation standards at four concentration levels were found quite 
acceptable according to the regulatory requirements, since their values are largely below the 
maximum of 10%, irrespective of the concentration level. 
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VI.3.2.4. Precision 
 
Precision is the closeness of agreement among measurements from multiple sampling 
of homogeneous sample under the recommended conditions. The precision of the analytical 
method was estimated by calculating repeatability and time-dependent intermediate precision 
at each concentration level. The relative standard deviation (RSD) values were calculated 
from the estimated concentrations. As can be seen from Table 2, the RSD values were found 
to be very low (between 0.2 and 0.9%), illustrating the excellent precision of the proposed 
method. 
 
VI.3.2.5. Accuracy 
 
Accuracy refers to the closeness of agreement between the test result and the accepted 
value, namely the conventionally true value. The accuracy of the analytical method takes into 
account the total error, i.e. both systematic and random errors, related to the test result. The 
upper and lower β-expectation tolerance limits expressed in relative bias (%) as a function of 
the introduced concentrations are presented in Table 2. The different tolerance limits of the 
mean relative bias did not exceed the acceptance limits for each concentration level. 
Therefore, the developed method can be considered as accurate over the whole concentration 
range investigated. 
 
VI.3.2.6. Linearity 
 
The linearity of an analytical method is the ability within a definite range, to obtain 
results directly proportional to the concentration (quantity) of the analyte in the sample. For 
all series, a regression line was fitted on the back-calculated concentrations of validation 
standards as a function of the introduced concentrations by applying the linear regression 
model based on least squares method. 
The results attesting the method linearity, namely the regression equation 
corresponding to that relationship with its coefficient of determination, are presented in Table 
2. Moreover, in order to demonstrate the method linearity, the approach based on absolute β-
expectation tolerance limits was applied. As can be seen in Fig. 6, the linearity of the present 
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method was demonstrated since the absolute β-expectation tolerance limits were within the 
absolute acceptance limits. 
 
VI.3.2.7. Detection and quantification limits 
 
The limit of detection (LOD) is the smallest quantity of the targeted substance that can 
be detected, but not accurately quantified in the sample. In the present study, the LOD was 
estimated to be the response corresponding to three times the signal to noise ratio. By 
applying this method, the LOD of the developed method was found to be equal to 0.02%. The 
limit of quantification (LOQ) of an analytical method is the lowest amount of the targeted 
substance which can be quantitatively determined under the experimental conditions 
prescribed with a well-defined accuracy, i.e., taking into account the systematic and random 
errors [13, 16]. As the accuracy profile was included inside the acceptance limits over the 
whole concentration range investigated, the first concentration level (0.1%) was considered as 
the LOQ, according to the selected regression model. Indeed, precision and trueness were 
demonstrated at this concentration level.  
 
Figure 6. Linearity profile of the developed method. The plain line is the identity line: Y=X, 
the dashed lines correspond to the accuracy profile i.e. to the β-expectation tolerance limits 
expressed in absolute values. The dotted curves represent the acceptance limits (±10%) 
expressed in the concentration unit. 
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Table 2. Validation results for R-ropivacaine using the linear regression model after square 
root transformation. 
Validation criteria R-Ropivacaine   
Response function Slope Intercept r
2
 
(k=3; m=5; n=2) (0.1-1.5%)    
Day 1 6.47  -0.341  0.9999  
Day 2 6.50  -0.356  0.9999  
Day 3 6.48  -0.337  0.9999  
    
Trueness (k=3; n=3)   Relative bias (%) 
0.1%   0.3  
0.2%   -0.85  
0.5%   -1.2  
1.5%   -0.25  
    
Precision (k=3; n=3) RSD (%)   
Repeatability  Intermediate precision 
0.1% 0.5   0.9  
0.2% 0.6   0.6  
0.5% 0.3   0.9  
1.5% 0.2   0.3  
    
Accuracy (k=3; n=3)  Relative β-Expectation tolerance 
limits (%) 
0.1%   [-2.79 , 3.46]  
0.2%   [-2.27 , 0.57]  
0.5%   [-5.12 , 2.79] 
1.5%   [-1.50 , 0.99] 
    
Linearity (k=3; m=4; n=3) (0.1-1.5%)    
Slope   0.9979   
intercept  -0.0015   
r
2
  1   
    
LOD (%)  0.02   
LOQ (%)  0.1   
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VI.4. Conclusion 
 
In this paper, a chiral LC method with Sepapak-4 as CSP in polar organic solvent 
chromatography mode, was developed to determine the enantiomeric purity of S-ropivacaine 
in an aqueous formulation. The method development shows the reversal of ropivacaine 
enantiomers elution order according to the acidic additive (TFA or FA).  
The method was then fully validated according to the strategy based on the accuracy 
profiles. Good performance with respect to selectivity, trueness, precision and accuracy, were 
obtained. The limits of quantification (0.1%), detection (0.02%) and the analysis time make 
the method suitable for rapid quality control of the enantiomeric purity of ropivacaine 
hydrochloride in an aqueous pharmaceutical formulation in comparison with the existing 
methods.  
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CHAPTER VII. 
 
LC METHOD FOR THE ENANTIOMERIC PURITY 
DETERMINATION OF S-AMLODIPINE WITH SPECIAL 
EMPHASIS ON REVERSAL OF ENANTIOMER ELUTION ORDER 
USING CHLORINATED CELLULOSE-BASED CHIRAL 
STATIONARY PHASES AND POLAR NON-AQUEOUS MOBILE 
PHASES 
  Chapter VII. 
 
126 
Summary 
 
A LC method was developed and prevalidated for the enantiomeric purity 
determination of S-amlodipine in polar organic solvent chromatography (POSC) using 
chlorine containing cellulose-based chiral stationary phases (CSPs). The concentration of 
formic acid (FA) (0.01-0.2%) in the mobile phase containing acetonitrile as the main solvent, 
was found to influence the elution order of amlodipine enantiomers as well as the 
enantioresolution. A reversal of the enantiomer elution order of amlodipine was only observed 
with CSPs with both electron-withdrawing (chloro groups) and electron-donating (methyl 
group) on the phenyl moieties of the chiral selector, namely Sepapak-2 and Sepapak-4. The 
highest enantioresolution (Rs: 4.1) value was obtained at the lowest FA concentration (0.01 
%) with Sepapak-4 as CSP and the enantiomeric impurity, R-amlodipine, eluted first under 
these conditions. Therefore the mobile phase selected for the prevalidation of the method 
consisted of ACN/0.1%DEA/0.01%FA and the temperature was set at 25°C. 
The prevalidation of the method by means of the strategy based on total measurement 
error and the accuracy profile led to the selection of the weighted (1/X
2
) linear regression as 
response function of the calibration curve within the matrix. The method was found to be 
selective and the limit of quantification was found to be about 0.5 µg/mL (0.05%) for R-
amlodipine while the limit of detection was close to 0.2 µg/mL (0.02%). Moreover no 
significant matrix effect was observed. 
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VII.1. Introduction 
 
Advances in chiral technology have led to the development of the pure enantiomers of 
new chiral drugs as well as previously marketed drugs as racemates (“chiral switch”) [1, 2]. 
The need to enhance the efficacy and the safety profile of modern drugs as well as economic 
reasons have resulted in an active promotion of the chiral switch in the pharmaceutical 
companies. Indeed, the potential benefits of this strategy include improvement of the 
therapeutic index, simplification of the dose–response relationship and more selective 
pharmacodynamic profile [1, 2, 3]. Moreover, the pharmaceutical companies can save their 
market share from erosion due to generic competitors by developing the single-enantiomer 
versions of their racemic drugs in order to get new patents and monopolize the market. 
Amlodipine, a long-acting L-type calcium-channel antagonist, is commercially 
available as a racemic mixture of (R)- and (S)-isomers. The comparison of the R(+)- and S(–)-
isomers activities has shown that the S(–)-isomer is 1000 times more potent than the R(+)-
isomer [4,5]. Moreover, clinical studies revealed that lower extremity edema was observed 
with S-amlodipine compared to the racemic mixture [6, 7, 8]. Thus, the chiral switch from 
racemic amlodipine to its S-enantiomer becomes evident since better tolerability and 
antihypertensive effects are expected. 
Different methods dedicated to the determination of amlodipine enantiomers in 
biological fluids were reported. The enantioseparation of amlodipine was successfully carried 
out in liquid chromatography using α1-acid-glycoprotein column [9,10] and in capillary 
electrophoresis with α-CD as chiral selector in the running buffer [11]. To the best of our 
knowledge, there is no published methods for the enantiomeric purity determination of 
amlodipine. 
The first aim of our work was to develop a LC method for the determination of R-
amlodipine in a pharmaceutical formulation of S-amlodipine using chlorine containing 
cellulose-based CSP. Indeed, these CSPs have been shown to develop high chiral 
discrimination abilities for chiral basic drugs in polar organic solvent chromatography [12-14] 
The nature and concentration of the acidic additive were found to be important parameters to 
optimize retention and enantioresolution of the tested drugs. Then the optimized LC method 
was prevalidated according to the strategy proposed by a Commission of the Société 
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Française des Sciences et Techniques Pharmaceutiques [15]. This strategy is based on the use 
of accuracy profiles which take into account the total error, i.e. estimation of systematic and 
random errors of measurement. 
 
 
VII.2. Experimental 
VII.2.1. Chemicals and reagents 
 
(R) and (S)-amlodipine base were generously provided by Prof. B. Chankvetadze. 
Amlodipine chemical structure is presented in Figure 1. Acetonitrile (ACN) of HPLC grade. 
Diethylamine (DEA), and formic acid (FA) pro analysis were obtained from Acros Organics 
(Geel, Belgium). Microcrystalline cellulose NF (Avicel
®
) was supplied by FMC Biopolymer 
(Brussels Belgium) and Magnesium stearate by RPL (Leuven, Belgium). Pregelatinized starch 
NF (Starch 1500
®
) and Colloidal silicon dioxide NF (Acrosil 200
®
) were supplied 
respectively by Colorcon (Indianapolis, USA) and Degussa AG (Franckfurt, Germany). 
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of amlodipine. 
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VII.2.2. Instrumentation 
 
The chromatographic system from Agilent Technologies (Waldbronn, Germany) 
consisted in a binary pump, a thermostated column compartment, a diode array detector and 
an automatic injector, all of 1200 series. The Chemstation software was used for system 
control and data acquisition. 
The chiral column Sepapak-2, Sepapak-4 and Sepapak-5 (250 mm x 4.6mm I.D.) was 
kindly provided by Sepaserve (Münster, Germany). The chiral selector adsorbed on 
aminopropylsilanized silica was cellulose tris (3-chloro-4-methylphenylcarbamate), cellulose 
tris (4-chloro-3 methylphenylcarbamate) and cellulose tris (3,5-dichlorophenylcarbamate) for 
Sepapak-2, Sepapak-4 and Sepapak-5 respectively, in the amount of 25% (w/w).  
The statistical calculations for validation were performed by means of e.noval version 
3.0 software (Arlenda, Liege, Belgium). 
 
 
VII.2.3. Standards solutions  
VII.2.3.1. Sample solutions used for method development  
 
Different stock solutions of R- and S-amlodipine were prepared by dissolving an 
accurately weighed amount of approximately 1 mg of each compound in 10 ml of ACN. The 
stock racemate solution was prepared by dissolving a weighed amount of approximately 1 mg 
for R amlodipine and 1.1 mg for S-amlodipine in 10 mL of ACN.  
 
 
VII.2.3.2. Sample solutions used for prevalidation 
 
A stock solution of R-amlodipine was prepared by dissolving an accurately weighed 
amount of approximately 5 mg of this compound in 100 mL of the LC mobile phase. Then 
subsequent dilutions in the mobile phase were achieved in order to obtain five calibration 
standards ranging from 0.5 to 15 µg/mL (m=5) (cf. Table 1).  
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Stock matrix solution was prepared by dissolving 14.4 mg of Starch 1500® 
formulation [16] of amlodipine besylate without its active ingredient in the LC mobile phase. 
This mixture was then centrifuged at 4500 g for 5 minutes and the supernatant was used for 
preparation of calibration standards. Five solutions were prepared by diluting the stock 
solution of R- amlodipine with the matrix solution to achieve calibration concentrations 
ranging from 0.5 to 15 µg/ml. Two replicates (n=2) were prepared per concentration level. 
Each solution was injected one time. The number of concentration levels was sufficient to 
generate different regression models with and without matrix. 
 
Table 1. Preparation of standard solutions related to R-amlodipine for prevalidation 
Concentration  level (% relative to  
1.0 mg/mL of S-amlodipine) 
Concentration of R-amlodipine (µg/mL) 
Calibration standards 
wihout the matrix 
Calibration standards 
within the matrix 
0.05 0.5 0.5 
0.1 1.0 1.0 
0.2 2.0 2.0 
0.5 5.0 5.0 
1.5 15.0 15.0 
total 10 samples/day 10 samples/day 
 
 
VII.2.4. Chromatographic conditions 
 
The mobile phases consisted of a mixture of acetonitrile, acidic additive and basic 
additive (v/v) and were pumped at a constant flow-rate of 1.0 mL.min-1. In all experiments, 
the basic additive percentage in the mobile phase was settled at 0.1 %. The injection volume 
was 20 µL. The analytes were detected photometrically at 240 nm and the temperature was 
settled at 25°C in all experiments.  
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VII.3. Results and discussion 
VII.3.1. Method development  
 
The screening of the chromatographic conditions for the enantioseparation of 
amlodipine was performed using two different mobile phases, namely 
ACN/0.1%DEA/0.1%TFA and ACN/0.1%DEA/0.2%FA (v/v/v), with a temperature settled at 
25°C. These conditions were selected in previous work using three chlorine containing 
cellulose based CSPs, namely Sepapak-2, Sepapak-4 and Sepapak-5 [12,13]. 
The mobile phase with formic acid (FA) as acidic additive showed good results with 
respect to enantioresolution, even if the retention times were higher with this additive, 
irrespective of the nature of the CSP (data not shown). On the contrary, the use of the mobile 
phase containing TFA as acidic additive did not give rise to the enantioseparation of 
amlodipine. 
In order to optimize the analysis time and the enantioresolution for  amlodipine, the 
concentration of FA in the mobile phase was tested from 0.01 and 0.2%. The results showed a 
significant effect of the FA concentration in the mobile phase on the retention and resolution 
of amlodipine enantiomers. 
 
 
VII.3.1.1. Effect of FA concentration on retention: reversal of elution 
 order 
 
Figs. 2 A, B and C present the retention times of the enantiomers of amlodipine on the 
three CSPs, using different concentrations of FA as acidic additive in the mobile phase. As 
can be seen in these figures, the retention of amlodipine enantiomers depends on the nature of 
the CSP. The lowest concentration of FA gave rise to the lowest retention of amlodipine 
enantiomers (<15 min) on all these CSPs. At higher FA concentrations, the retention times 
increased and passed through a maximum at 0.1% FA for Sepapak-2 and Sepapak-4 and at 
0.05% FA for Sepapak-5. Moreover, the highest retention times obtained for amlodipine 
enantiomers using Sepapak-5 were lower compared to those found on the other CSPs. 
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Figure 2. Influence of the percentage of formic acid (FA) on the retention and elution order of 
amlodipine enantiomers. 
Mobile phase: ACN/0.1% DEA/(0.01- 0.2)% FA; Flow rate: 1 mL/min; CSP: Sepapak-2 (A), 
Sepapak-4 (B), Sepapak-5 (C). Other conditions see Section 2. 
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It is particularly important to note that a reversal of the enantiomer elution order was observed 
on both Sepapak-2 and Sepapak-4. In both cases, R-amlodipine eluted first at lower FA 
concentrations, less than 0.02 % with Sepapak-2 and less than 0.035% with Sepapak-4 in the 
mobile phase, while S-amlodipine eluted first at higher FA concentrations (cf. chromatograms 
obtained with Sepapak-4 in Figs. 3 A and B). No reversal of the enantiomer elution order was 
obtained on Sepapak-5. 
 
 
 
Figure 3. Chromatograms showing the reversal of amlodipine enantiomers elution order 
according to the concentration of the acidic additive (FA). 
Mobile phase: ACN/0.1% DEA/0.01% FA (A), ACN/ 0.1% DEA/0.2% FA (B); Flow rate: 1 
mL/min; CSP: Sepapak-4. Peaks: (R) R-amlodipine and (S) S-amlodipine: Others conditions 
see Section 2. 
 
 
This unusual phenomenon is a key issue in LC determination of the enantiomeric 
purity of chiral drugs [17,18]. Indeed, it is usually desirable to detect the minor component in 
front of the major one in this kind of analysis because several studies have shown that the 
limits of detection and quantification were lower and that the reproducibility of the 
determination was higher for the minor enantiomer when it eluted first [19-21].  
(A) (B) 
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Many reversals of elution order were described in literature. In 1988, a reversal of the 
elution order was observed by Hermansson and Schill for the enantioseparation of 
pseudoephedrine using an α-acid glycoprotein-based (AGP) stationary phase. The authors 
have related this phenomenon to the addition of octanoic acid to the mobile phase [22]. Two 
years later, Haginaka et al. reported a reversal of the elution order of propranolol enantiomers 
and its ester derivatives depending on the nature of the organic modifier added to the mobile 
phase using ovomucoid-bonded silica as CSP [23]. A temperature-dependent elution order 
reversal was first reported by Pirkle and Murray using a π-basic proline-derived CSP in 1993 
[24]. Okamoto et al. reported in 1991 the first reversal of the enantiomer elution order on a 
cellulose-based CSP (Chiralcel OJ) [25]. They found that the reversal of elution order of 
pyriprofen enantiomers (an insect growth regulator) using this CSP was associated with the 
change in the mobile phase of the nature of the organic modifier (alcohols). Balmér et al. [26] 
observed also a temperature-dependent reversal of the enantiomer elution order when a 
derivative of metoprolol, H170/40, was enantioseparated with Chiralcel OD as CSP. In almost 
all these reversals of the enantiomeric elution order, the authors suggested that solvation 
and/or conformation of both the solute enantiomers and the CSP can be affected by the 
change of the nature of the polar organic modifier. Likewise, changes in temperature can 
induce conformational changes of a polymeric selector. Recently, we reported the reversal of 
the elution order of ropivacaine enantiomers induced by the change of the nature of the acidic 
additive (TFA or FA) in the mobile phase using the same chlorine containing cellulose-based 
CSPs [14].  
The reversal of elution order of amlodipine enantiomers observed on Sepapak-2 and 
Sepapak-4 could be related to the presence of both electro-withdrawing (chlorine) and 
electron-donating (methyl) substituents on the phenyl moieties of the chiral selector since no 
reversal was obtained on Sepapak-5, which possesses only chloro substituants on its phenyl 
moieties. Indeed, these mixed substituents may create a regular arrangement of grooves along 
the carbohydrate (cellulose) chains which can serve as enantioselective binding pockets, as 
suggested by Lämmerhofer [27]. A change of the FA concentration in of the mobile phase 
could have induced a modification of the conformation of the polymeric selector that leads to 
the reversal of the elution order of amlodipine enantiomers. 
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VII.3.1.2. Effect of FA concentration on the enantioresolution 
 
As can be seen in Figure 4, the enantioresolution of amlodipine was found to strongly 
depend on the FA concentration in the mobile phase. As expected, enantioresolution values 
passed through zero, corresponding to a FA concentration of 0.035 % when Sepapak-4 was 
used as CSP, due to the reversal of the elution order of amlodipine enantiomers at this FA 
concentration. A similar trend can be observed with Sepapak-2 and the concentration 
corresponding to the coelution of both enantiomers of amlodipine is situated in this case 
between 0.02 and 0.03% FA (cf. Fig. 2 A). Even though enantioresolution values started to 
increase at FA concentrations higher than 0.02% when Sepapak-5 was used as CSP, the se 
values remained lower than those obtained with the two other CSPs. 
It is noteworthy that the highest enantioresolution value (Rs: 4.1) was obtained using 
Sepapak-4 with a FA concentration of 0.01% in the mobile phase. Therefore, the mobile 
phase selected for the prevalidation of the method for the enantiomeric purity determination 
of S-amlodipine was made of ACN/0.1% DEA/ 0.01% FA since the enantiomeric impurity 
(i.e. R-amlodipine) is then the first eluting peak. 
 
 
 
 
 
 
 
Figure 4. Influence of FA concentration in the mobile phase on the enantioresolution of 
amlodipine using the three chlorine containing CSPs. 
Mobile phase: ACN/0.1% DEA/(0.01- 0.2)% FA; Flow rate: 1 mL/min; 
Other conditions see Section 2. 
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 VII.3.2. Prevalidation 
On the basis of the prevalidation protocol proposed by the “Société Française des 
Sciences et Techniques Pharmaceutiques (SFSTP)” Commission, the experiments achieved 
during the prevalidation step deal with the analysis of the response function and the selection 
of the most appropriate model for the calibration curve in the validation step. For that 
purpose, the SFSTP approach based on two-sided 95% β-expectation tolerance intervals for 
total measurement error including systematic and random errors and accuracy profiles 
obtained with and without the matrix was used [15, 28-30]. The concept of accuracy profile 
was also applied to estimate the limit of quantification (LOQ) and the range over which the 
method could be validated. Moreover, the method selectivity was evaluated and the limit of 
detection (LOD) was estimated.  
 
  VII.3.2.1. Selectivity 
 
Typical chromatograms obtained after analysis of matrix solution containing or not R-
amlodipine as well as a reference solution of the compound of interest were compared in 
order to check the absence of components likely to interfere in the quantification of R-
amlodipine. As can be seen in Figs. 5A, B and C, no interference was observed at the 
retention time of the peak corresponding to R-amlodipine. Moreover, matrix solution 
containing S-amlodipine (1 mg/mL) and spiked with 1 µg/mL (Fig. D) or 5 µg/mL (Fig. E) of 
R-amlodipine was analysed (cf. Fig. 5D and E). As can be seen in these figures, the peak of 
R-amlodipine can be identified and quantified. 
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Figure 5. Typical chromatograms of a) a matrix solution; b) R-amlodipine diluted in the 
mobile phase (1 µg/mL); c) R-amlodipine spiked in the matrix solution (1 µg/mL); d) a 
solution of S-amlodipine (1 mg/mL ) spiked with R-amlodipine (1 µg/mL); e) a solution of 
S-amlodipine (1 mg/mL ) spiked with R-amlodipine (5 µg/mL). 
Mobile phase: ACN/0.1% DEA/0.01% FA, Flow-rate: 1 mL/min; CSP: Sepapak-4. Other 
conditions see Section 2. 
(A) 
(B) (C) 
(D) (E) 
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VII.3.2.2. Selection of the calibration model 
 
Two independent calibration solutions with and without the matrix were prepared each 
day of prevalidation. 
Several regression models were fitted to the calibration standards prepared with and 
without matrix. From each regression model obtained, the concentrations of the calibration 
standards were back-calculated in order to determine, at each concentration level, the mean 
relative bias, the relative standard deviation for intermediate precision as well as the upper 
and lower β-expectation tolerance limits at 95% [15]. 
Taking into account the prevalidation data, several accuracy profiles were plotted to 
select the most suitable regression model for the intended use of the analytical method, as 
illustrated in Figure 6. Four response functions (with and without the matrix), namely the 
simple linear regression, the weighted (1/X and 1/X
2
) linear regression models and the linear 
regression model obtained after logarithm transformation were tested. The acceptance limits 
were set at ±5% according to the regulatory requirements [15, 28-30].  
All these response functions, except the simple linear model, allowed testing the 
capability of the method over the concentration range considered, since the tolerance intervals 
were totally included inside the acceptance limits as shown in Fig. 6. However, the weighted 
(1/X
2
) linear regression model observed with the matrix seems to be the best. Indeed, the 
relative error is the lowest especially at the two first concentration levels (cf. Fig. 6F). The 
variability of the results is also weak. However, the matrix effect seem to be limited. Table 2 
presents the prevalidation results obtained by applying this weighted linear regression model. 
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Figure 6. Accuracy profiles with (down) and without (upper) the matrix obtained using a;b) a linear regression model. c;d) a weighted linear 
regression model with a weight equal to 1/X. e;f) a weighted linear regression model with a weight equal to 1/X
2
. g;h) a linear regression model 
after logarithm transformation. The plain line is the relative error (%), the dashed lines correspond to the accuracy profile i.e. to the β-expectation 
tolerance limits expressed in relative error, and the dotted curves represent the acceptance limits (±5%). 
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VII.3.2.3.Trueness 
 
Trueness refers to the closeness of agreement between a conventionally accepted value 
or reference value and a mean experimental one. It is expressed in terms of relative bias (%). 
As can be seen in Table 2, the relative biases assessed from the calibration standards within 
the matrix at five concentration levels were found quite acceptable, since their values are 
largely below 5%, irrespective of the concentration level. 
 
VII.3.2.4. Precision 
 
Precision was estimated by calculating repeatability and time-dependent intermediate 
precision at five concentration levels. The relative standard deviation (RSD) values were 
calculated from the estimated concentrations. As can be seen in Table 2, the RSD values were 
found to be very low (between 0.06 and 0.7%), illustrating the very low variability of the 
proposed method. 
 
VII.3.2.5. Accuracy 
 
Accuracy refers to the closeness of agreement between the test result and the accepted 
value, namely the conventionally true value. The accuracy of the analytical method takes into 
account the total error related to the test result. The upper and lower β-expectation tolerance 
limits expressed in relative bias (%) as a function of the introduced concentrations in the 
matrix are presented in Table 2. The different tolerance limits of the mean relative bias did not 
exceed the acceptance limits for each concentration level. Therefore, the developed method 
could be considered as accurate over the whole concentration range investigated. However, it 
should be more interesting to perform the validation within a restrictive concentration range, 
namely 1 to 15 µg/mL corresponding to 0.1 and 1.5 % of R-amlodipine in S-amlodipine 
pharmaceutical formulation. 
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Table 2. Prevalidation results for R-amlodipine using the weighted (1/X
2
) linear regression 
model within the matrix  
Prevalidation criteria R-amlodipine   
Response function Slope Intercept r
2
 
(k=3; m=5; n=2) (0.5-15µg/mL)    
Day 1 36.73  -0.9147  0.9999  
Day 2 36.64  -0.7149 0.9999  
Day 3 36.68  -0.7773 0.9999  
    
Trueness (k=3; n=2)   Relative bias (%) 
0.5 µg/mL   0.48 
1.0 µg/mL   1.16 
2.0 µg/mL   -0.05 
5.0 µg/mL   -1.02 
15 µg/mL   0.39 
    
Precision (k=3; n=2) RSD (%)   
Repeatability  Intermediate precision 
0.5 µg/mL 0.7  0.7 
1.0 µg/mL 0.3  0.3 
2.0 µg/mL 0.4  0.4 
5.0 µg/mL 0.3  0.3 
15 µg/mL 0.06  0.12 
    
Accuracy (k=3; n=2)  Relative β-Expectation tolerance 
limits (%) 
0.5 µg/mL   [-2.44 , 1.48] 
1.0 µg/mL   [0.31 , 2.01] 
2.0 µg/mL   [-1.07 , 0.97] 
5.0 µg/mL   [-1.73 , -0.31] 
15 µg/mL   [-0.08 , 0.85] 
    
Linearity (k=3; m=5; n=2)  
(0.5-15µg/mL) 
   
Slope   1.004  
intercept  -0.0148   
r
2
  1   
    
LOD (µg/mL)  0.15   
LOQ (µg/mL)  0.5   
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  VII.3.2.6. Linearity 
 
The linearity of an analytical method is the ability within a definite range, to obtain 
results directly proportional to the concentration (quantity) of the analyte in the sample. For 
all series, a regression line was fitted on the back-calculated concentrations of calibration 
standards as a function of the introduced concentrations by applying the linear regression 
model based on least squares method. 
The slope and intercept of the equation corresponding to that relationship as well as 
the coefficient of determination are presented in Table 2. 
 
VII.3.2.7. Detection and quantification limits 
 
The limit of detection (LOD) is the smallest quantity of the targeted substance that can 
be detected, but not accurately quantified in the sample. In the present study, the LOD was 
estimated using the mean intercept of the calibration model and the residual variance of the 
regression. By applying this computation method, the LOD of the developed method was 
estimated to be equal to 0.15µg/mL. 
 The limit of quantification (LOQ) of an analytical method is the lowest amount of the 
targeted substance which can be quantitatively determined under the experimental conditions 
prescribed with a well-defined accuracy [15, 28]. As the accuracy profile was included inside 
the acceptance limits over the concentration range investigated, the first concentration level 
(0.05%) could be considered as the LOQ, according to the selected regression model.  
 
 
VII.4. Conclusion 
 
The determination of the enantiomeric purity of S-amlodipine in a pharmaceutical 
formulation was developed in POSC using chlorine containing cellulose based CSPs. The 
results showed a reversal of the elution order of amlodipine enantiomers, related to the 
concentration of FA in the mobile phase. This reversal of the enantiomer elution order 
occurred only on cellulose-based CSPs with both electron-withdrawing (chlorine atoms) and 
electron-donating (methyl group) on the phenyl moieties of the chiral selector.  
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Furthermore, the method was prevalidated according to the strategy based on the 
accuracy profile. The method was found to be selective, precise and accurate and no matrix 
effect could be observed. The response function appropriate for this method was found to be 
the weighted (1/X
2
) linear regression model. The limit of quantification was 0.5µg/mL 
(0.05%) of R-amlodipine. However, for the method validation it would be better to settle the 
lowest concentration at 1µg/mL (0.1%) of R-amlodipine.  
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The recognition abilities of three new chiral stationary phases, Sepapak-2, and 
Sepapak-4 and Sepapak-5, towards the enantiomers of thirteen (13) chiral basic 
pharmaceuticals with widely different structures and polarities, have been studied in polar 
organic solvent chromatography (POSC) with acetonitrile as the main solvent. 
 In the first part of this thesis, we studied the influence of temperature, organic 
modifiers, nature and concentration of acidic additves on retention, selectivity and 
enantioresolution of these chiral drugs using Sepapak-4. An univariate approach was used for 
that purpose. The temperature (15-35°C) was found to have a rather limited effect on 
enantioresolution. However, for celiprolol, a significant efficiency enhancement led to 
enantioresolution improvement. Polar (methanol) and non-polar (n-hexane) organic modifiers 
had opposite effects on retention and enantioresolution indicating a normal-phase 
behaviour.The addition of n-hexane (10%) in the mobile phase increased the retention and 
enantioresolution of most of the studied compounds, unlike methanol. The importance of the 
nature and concentration of the acidic additive (TFA, FA and AcA) in the mobile phase on 
retention, selectivity and enantioresolution was also demontrated. FA was found to induce the 
highest retention while the lowest was obtained using TFA. Moreover the influence of the 
acidic additive (FA and AcA) concentration in the mobile phase on retention and 
enantioresolution was found to be rather molecule dependent even though FA generally led to 
better enantioresolution values compared to AcA. Therefore, two groups could be 
distinguished according to the acidic additive. The first group consisted of all studied beta 
blockers (except oxprenolol, propranolol and sotalol) and prilocaine for which 
enantioresolution was better with TFA as acidic additive. The second group for which a better 
enantioseparation was obtained with FA, was constituted by the rest of the studied chiral 
compounds. Although the mechanisms of chiral recognition could not be completely 
explained, the acidic additive effects seems be related to the presence of both electron-
withdrawing (chlorine) groups and electron-donating (methyl) groups on the phenyl moieties 
of the chiral selector of Sepapak-4. 
In the second part of this thesis, experimental designs were used to perform the 
screening and optimization of the factors previously studied. The screening step performed 
using a fractional factorial design confirmed that the effects of the acidic additive and n-
hexane on enantioresolution were significant while temperature and the nature of the basic 
additive were found to have a limited effect. The optimization step carried out with a face 
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centered central composite design led to optimal enantioresolution values and the deduced 
conditions for rapid screening could be applied to other chiral compounds. 
In the third part of this thesis, three rapid screening conditions, namely ACN/0.1% 
DEA/0.1%TFA, ACN/0.1% DEA/0.2% FA and ACN/0.1% DEA/0.2% AcA, were applied to 
the three studied CSPs (Sepapak-2, Sepapak-4 and Sepapak-5). They revealed the 
complementarity of the chiral discrimination abilities of these CSPs in polar organic solvent 
chromatography. Obviously, a rapid screening could be carried out with only four 
experiments involving Sepapak-4 with ACN/0.1% DEA/0.1%TFA and ACN/0.1% 
DEA/0.2% FA as mobile phases and Sepapak-5 with ACN/0.1% DEA/0.2% FA and 
ACN/0.1% DEA/0.2% AcA as mobile phases. 
In the application part of this thesis, enantioseparation methods using these CSPs were 
developed to evaluate the enantiomeric purity of S-ropivacaine and S-amlodipine, 
respectively, in pharmaceutical formulations. With both compounds, a phenomenon of 
reversal of the enantiomer elution order could be observed. The reversal of the enantiomer 
elution order of ropivacaine caused by the change of the nature of acidic additive (TFA or 
FA) in the mobile phase occurred only on the two CSPs with both electron-withdrawing 
(chlorine) and electron donating (methyl) groups on the phenyl moieties of the chiral selector, 
Sepapak-2 and Sepapak-4. The reversal of the enantiomer elution order of amlodipine caused 
by the change in the formic acid concentration in the mobile phase occurred on the same 
CSPs as for ropivacaine. The change of the nature or the concentration of the acidic additive 
could have induced a modification of the conformation of the chiral selector, leading to the 
reversal of the enantiomer elution order.  
The optimised method for the enantiomeric purity evaluation of S-ropivacaine in a 
pharmaceutical formulation (Naropin, 10 mg/mL aqueous solution) was validated by means 
of the strategy based on the use of the accuracy profiles. The method truness, precision and 
accuracy were determined and found to be satisfactory over the working concentration range. 
A limit of quantification (LOQ) of 0.1% was reached while the limit of detection (LOD) was 
0.02% for R-ropivacaine. 
Regarding amlodipine, the developed method was prevalidated according to the same 
approach as for ropivacaine. The selectivity, linearity and precision of the method were 
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demonstrated. Futhermore, no matrix effect was observed and the concentration range for 
method validation was found to be 1-15µg/mL. 
As a general conclusion, this thesis work demonstrates the essential role that the 
mobile phase acidic additive plays in the optimization of enantioseparations using these 
chlorine containing cellulose-based CSPs together with polar organic mobile phases. Indeed, 
the retention, selectivity and enantioresolution of chiral basic compounds and even the 
enantiomer elution order for some molecules, such as ropivacaine and amlodipine, can be 
modulated by the nature and concentration of the acidic additive in the mobile phase. 
Among the three tested CSPs, it is no doubt Sepapak-4 that must be considered as the 
first choice in this POSC mode, since this CSP was found to give the highest resolution power 
towards the enantiomers of basic drugs in most cases. Sepapak-5, with two chloro groups on 
its phenyl moieties, has shown significant differences in chiral recognition properties 
compared to Sepapak-4 and can therefore be seen as an interesting alternative. 
At the end of this thesis, we are perfectly conscious of the fact that there are still 
several other aspects that it would have been worth studying but we have not been able to 
tackle them by lack of time. 
For example, it would be interesting to study more in detail the behavior of these CSPs 
towards acidic and neutral compounds in order to extend the proposed rapid screening 
strategy to these classes of compounds.  
Several polar organic solvents were tested as main components of the mobile phase 
but only acetonitrile, which was found to be the most suitable solvent in preliminary 
experiments, was used in this thesis. It would certainly be worth testing POSC systems with 
other solvents, such as methanol or ethanol, either pure or in mixtures, since they might lead 
to different chiral recognition mechanisms on these CSPs. 
Finally, it would be also of interest to investigate the use of these CSPs in other 
column formats, in particular in columns with small diameters, either in micro-LC or in CEC, 
and to try to couple these columns with a mass spectrometric detection in order to develop 
highly sensitive methods for the stereoselective determination of small amounts of drug 
enantiomers in biological fluids. 
 
 152 
 
 
 
 
 
 
  Appendix I 
 
153 
 
 
 
 
 
 
 
 
 
APPENDIX I 
 
 
 
   
 
154 
  Appendix I 
 
155 
List of publications 
 
1.“Enantioseparation of basic pharmaceuticals using cellulose tris(4-chloro-3- 
methylphenylcarbamate) as chiral stationary phase and polar organic mobile phases” 
K.S.S. Dossou, P. Chiap, B. Chankvetadze, A.-C. Servais, M. Fillet, J. Crommen, Journal of 
Chromatography A 1216 (2009) 7450-7455. DOI: 10.1016/j.chroma.2009.05.081. 
 
2.“Optimization of the LC enantioseparation of chiral pharmaceuticals using cellulose 
tris(4-chloro-3-methylphenylcarbamate) as chiral selector and polar non-aqueous 
mobile phases” 
K.S.S. Dossou, P. Chiap, B. Chankvetadze, A.-C. Servais, M. Fillet, J. Crommen, Journal of 
Separation Science 33 (2010) 1699-1707. DOI: 10.1002/jssc.201000049. 
 
3.“Development and validation of LC method for the enantiomeric purity determination 
of S-ropivacaine in a pharmaceutical formulation using a recently commercialized 
cellulose-based chiral stationary phase and polar non-aqueous mobile phase” 
K.S.S Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen, Journal of Pharmaceutical and 
Biomedical Analysis 54 (2010) 687-693 DOI: 10.1016/j.jpba.2010.10.020. 
 
4.“Evaluation of chlorine containing cellulose-based chiral stationary phases for the LC 
enantioseparation of basic pharmaceuticals using polar non-aqueous mobile phases” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen, Journal of Separation Science, 
in press. 
 
  Appendix I 
 
156 
5.“LC method for the enantiomeric purity determination of S-amlodipine with special 
emphasis on reversal of enantiomer elution order using chlorinated cellulose-based 
chiral stationary phases and polar non-aqueous mobile phases” 
K.S.S. Dossou, P.A. Edorh, P. Chiap, B. Chankvetadze, A.-C. Servais, M. Fillet, J. Crommen, 
(submitted for publication in Journal of Pharmaceutical and Biomedical Analysis ). 
 
  Appendix II 
157 
 
 
 
 
 
 
 
      
 
 
APPENDIX II 
158 
  Appendix II 
159 
 
List of oral communications, posters and contributions to oral 
communications throughout the Ph.D. 
 
“Development and validation of LC method for determination of enantiomeric purity of 
S-ropivacaine in a pharmaceutical formulation using a recently commercialized 
cellulose based chiral stationary phase and non-aqueaous mobile phases.” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen.  
Poster presentation at Drug Analysis 2010 (Antwerp, Belgium), September 21-24, 2010.  
 
“Evaluation of recently developed cellulose-based chiral stationary phases for the LC 
enantioseparation of basic pharmaceuticals using polar non-aqueous mobile phases.” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen. 
Poster presentation at 34th International Symposium on High Performance Liquid Phase 
Separations and related techniques, "HPLC 2009" (Dresden, Germany), June 2009. 
 
“A screening study of chiral pharmaceutical using tris(4-chloro-3-
methylphenylcarbamate) of cellulose-based stationary phase and polar organic phases.” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen. 
Poster Presentation at 33rd International Symposium on High Performance Liquid Phase 
Separations and related techniques, "HPLC 2008" (Kyoto, Japan), December, 2008.  
 
“Comparison of different cellulose based chiral stationary phases for the LC 
enantioresolution of basic drugs using polar organic mobile phases.” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen. 
  Appendix II 
160 
Contribution to oral communication at 19th International symposium on Pharmaceutical & 
Biomedical Analysis, “PBA 2008” (Gdansk, Poland), June 2008. 
 
“Enantioséparation de substances médicamenteuses basiques par chromatographie 
liquide à l’aide d’une nouvelle phase stationnaire chirale et de phases mobiles polaires 
non aqueuses.” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen. 
Oral communication at Forum «des Jeunes Chercheurs du CIRM» (Liege, Belgium), February 
02 2008. 
 
“HPLC enantioseparation of basic drugs using recently developed polysacharide-based 
CSPs with polar organic mobile phases.” 
K.S.S. Dossou, P. Chiap, A.-C. Servais, M. Fillet, J. Crommen. 
Contribution to oral communication at 12th International Meeting on Recent Development in 
Pharmaceutical Analysis, “RDPA 2007” (Elbe Island, Italy), September 2007. 
 
“HPLC enantioseparation of basic pharmaceuticals using a new polysaccharide-based 
chiral stationary and non-aqueous polar mobile phases.” 
K.S.S. Dossou, S. Ghiani, P. Chiap, A.-C. Servais, M. Fillet, J.Crommen. 
Poster presentation at 31st International Symposium on High Performance Liquid Phase 
Separations and Related Techniques, "HPLC 2007" (Gand, Belgium), June 21-24, 2007. 
